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CHAPTER 1 
Introduction 

INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is an autoimmune disease 
which may affect almost every organ of the body; clinical 
manifestations such as arthralgias, fever, vasculitis, 
serositis, nephritis and central nervous system involvement 
may occur in these patients. The disease is characterized by 
the formation of a variety of autoantibodies, notably anti-
nuclear antibodies such as antibodies that bind to double 
stranded DNA (anti-DNA) '. This type of autoantibodies is 
highly specific for SLE 2 and is considered to be a marker of 
disease activity 3"5. With respect to the development of 
glomerulonephritis, one of the most severe disease 
manifestations in these patients, antibodies of the IgG class 
with a relative high avidity for doublestranded DNA, and the 
property to activate complement, are associated with renal 
disease *, although the evidence for a nephritogenic role of 
these anti-DNA antibodies is mainly circumstantial. 
For many years SLE and especially SLE nephritis has been 
considered as a classical example of an immune complex 
disease, in which the deposition of DNA/anti-DNA complexes 
within the glomerulus was held responsible for the 
inflammation and subsequent glomerular damage in these 
patients 7. A nephritogenic role of anti-DNA antibodies is 
sustained by studies which showed the presence of anti-DNA 
antibodies in affected kidneys from SLE patients or mice 
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suffering from SLE like syndromes 8"11. A number of mechanisms 
have been proposed for the deposition of anti-DNA in the 
glomerulus 12·13 (Table 1) . 
Table 1. Possible mechanisms for the deposition of anti-DNA in 
the glomerulus. 
1. Passive entrapment of DNA/anti-DNA complexes. 
2. Affinity of DNA for renal structures. 
3. Binding of cationic immune complexes, antigens or 
antibodies to the negative charge of the GBM. 
4. Cross-reactivity of anti-DNA antibodies with glomerular 
structures. 
First, it has been suggested that circulating immune complexes 
containing anti-DNA antibodies can become passively trapped in 
the glomerular basement membrane (GBM). A second possibility 
is that DNA has a certain affinity for renal structures M,li 
which thereby can lead to either binding of circulating immune 
complexes or in situ immune complex formation with circulating 
anti-DNA antibodies which bind to planted DNA. However, 
evidence for the presence of DNA in the circulation, either 
free or bound to anti-DNA antibodies, or the presence of DNA 
in glomerular deposits, is controversial and questionable 
(reviewed by Fournie 1 2 ) . Furthermore, studies concerning the 
glomerular binding of DNA after intravenous injection into 
experimental animals were either unsuccessful because DNA was 
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cleared rapidly from the circulation by the liver 16'17 or they 
reported glomerular binding without showing the precise 
localization in the glomerulus at ultrastructural level 18'19. 
Also administration of exogenous DNA/anti-DNA complexes into 
experimental animals failed to result in a significant 
glomerular deposition of anti-DNA antibodies ^22. A third 
possibility is that the polyanionic charge of the GBM may 
enhance antigen trapping or binding of antibodies. A 
prerequisite for binding via this mechanism is a cationic 
charge of either the antigen or the antibody. Although a 
nephritogenic role of cationic antibodies has been proposed 
^
23
, little or no attention has been paid to the involvement of 
a cationic autoantigen in the development of SLE nephritis. 
Finally, it has been proposed that anti-DNA antibodies can 
bind directly to renal antigens due to crossreactions of anti-
DNA antibodies with intrinsic components of the glomerulus **. 
Studies in experimental animals to prove this mechanism, so 
far only induced mesangial immunoglobulin deposits in some 
studies Z5M. Taken together, experimental models to produce the 
deposition of anti-DNA antibodies along the capillary wall as 
seen in SLE kidneys have so far been unsuccessful. 
Previous work from our laboratory by Faaber et al introduced 
the concept of direct binding of anti-DNA antibodies to 
intrinsic components of the glomerulus, especially glomerular 
Heparan sulphate (HS) ^. HS is the glycosaminoglycan side 
chain of HSPG, which is an intrinsic constituent of the GBM. 
This HSPG is the major proteoglycan of the GBM and the strong 
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negative charge of this molecule is responsible for the 
charge-selective permeability of the GBM ^30. This concept was 
supported by studies which showed that anti-DNA antibodies can 
crossreact with several other molecules such as phospholipids 
31
·
32
, cell surface proteins " and different cell types 34,35. 
Based on these findings we postulated that direct binding of 
anti-DNA antibodies to HS within the GBM might be an important 
event in the development of SLE nephritis. Initial studies 
with monoclonal antibodies seemed to support this idea as 
discussed in chapter 2. 
However, when studies were in progress with regard to the 
cross-reactions of monoclonal anti-DNA antibodies with HS, we 
found that anti-DNA producing hybridoma culture supernatants 
contained DNA/anti-DNA complexes, which could disturb the 
reactivity pattern of the anti-DNA antibodies considerably ", 
Because of the negative charge of DNA the presence of this 
molecule in the immune complex did not provide a logical 
explanation for the binding of anti-DNA to another anionic 
molecule like HSPG. Therefore, studies were performed to 
investigate whether other nuclear antigens were present in 
these complexes, especially antigens with a cationic 
character, which through charge-charge interactions could be 
responsible for the binding to HSPG. In the cell nucleus DNA 
is associated with histones, a set of highly cationic 
proteins, thereby forming nucleosomes, the unit particle of 
chromatin 37. Supported by the findings of Jacob et al 38, who 
reported that the binding of anti-DNA to cell-surface protein 
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was mediated via DNA/histone particles and the postulation 
introduced by Fournie ,2 that not free DNA but DNA bound to 
histones are involved in the pathogenesis of lupus nephritis, 
we studied whether such DNA/histone particles or nucleosomes 
were also responsible for the binding of anti-DNA to HS and 
the GBM. 
Aim of the study; 
The aim of this study was to gain more insight into the 
pathogenic role of anti-DNA antibodies in the development of 
SLE nephritis. For this purpose the binding of anti-DNA 
antibodies to glomerular components, in particular glomerular 
HS, was studied both in vitro and in vivo. The clinical 
relevance of the binding of anti-DNA to HS was studied by 
using bloodsamples from SLE patients with different disease 
manifestations. In addition, the involvement of other 
autoantibodies besides anti-DNA in the pathogenesis of renal 
disease was investigated in two experimental models of SLE-
nephritis. 
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Binding of anti-DNA antibodies to glomerular heparan sulfate: 
a new clue for the pathogenesis of SLE nephritis?* 
J H M BLRDEN', R M TERMAAT1, К BRINKMAN*, R JT SMEENK*. A J G SWAAK*. Ρ FAABFR1, К ASSMANN3, 
L P W J vd HEUVEL4 and J Η VEERKAMP' 
Departments of Nephrology, ' Rheumatology, ' Pathology, * Biochemistry University of Nijmegen, Nijmegen and , Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands 
Binding of anti-DNA antibodies to glomerular heparan sulfate* a 
new clue for the pathogenesis of SI E nephritis9 Antibodies against 
heparan sulfate (HS) were detected in sera from patients with active 
systemic lupus erythematosus (Ы_Е) and in sera from MRL/I mice 
with a spontaneous SLE like disease By inhibition studies it was 
shown that this reacuvuy towards HS was due to cross reactivity of 
anti DNA antibodies Immunoglobulin clutcd from human and 
mouse kidneys with diffuse proliferative SLE glomerulonephritis also 
bound to HS This crossreaction of anti DNA antibodies was further 
substantiated by the finding that 17 ou of 42 anti DNA monoclonal 
antibodies (mAb) also bound to HS, 11 out of 17 HS positive mAb 
bound to heparan sulfate proteoglycan (HSPO) purified from human 
glomerular basement membranes (GBM) and 7 out of 42 bound 
directly to isolated human GBM loops The binding to HS HSPG, 
and GBM could be inhibited in a dose dependent manner by DNA In 
a retrospective analysis of sera from 10 SI F patients m which 6 16 
serum samples per patient were studied, wc found in all 5 episodes of 
onset or exacerbation of a SLE nephritis an anti HS activit> in the 
serum, prior to onset of the nephritis In 4 episodes of onset orexacer 
bation of non renal manifestations, anti HS activity was only found 
in the serum during one episode Based on these studies we postulate 
thai binding of and DNA antibodies to HS within the GBM may be 
an important immunopathological event in (he development of SLE 
nephritis 
Key words Ann DNA antibodies — SLE glomerulonephritis — 
crossreactivity — heparan sulfate — heparan sulfate pro 
teoglycan — glomerular basement membrane 
Systemic lupus erythematosus (SLE) is an autoimmune 
disease characterized by the presence in serum of antibodies 
reacting with a great variety of autoantigens Antibodies direc­
ted againsl dsDNA are considered as the major serological 
marker of this disease [30] SLE is generally regarded as an 
immune complex mediated disease in which depositions of cir­
culating DNA anti-DNA complexes in different tissues are held 
responsible for the development of the various disease mam 
fes tat ι on s In this concept deposition of immune complexes in 
the glomeruli leads to the onset of nephritis [18] Several stu­
dies have shown beyond any doubt an association between high 
levels of anti-DNA antibodies in the circulation and the deve 
lopment of SLE nephritis Furthermore the presence of high 
avidity anti-DNA antibodies has been demonstrated in eluates 
from kidneys with active SLE nephritis [17, 20, 36] However, 
the presence of the presumed antigen DNA in the circulation, 
immune complexes, or in glomerular deposits has not been 
proven unequivocally 
* This work was supported by grants from the Netherlands League 
against Rheumatism 
Fixation des an (korps anti-ADN au sulfate d'heparan gloménilaire 
une explication nouvelle pour le développement de la néphrite lupique. 
Des anticorps diriges contre le sulfate d'heparan (HS) ont ele detectes 
dans les scrums de patients atteints de lupus erythemateux disseminé 
(LED) actif et dans les serums de souris MRL/1 présentant un I ED 
spontane Par des etudes d'inhibition, cette réact i vité a 1 egard de HS 
s'est révélée être croisée avec celle des anticorps anti ADN L'immuno-
globuline eluée des reins humains et murins atteints de glomerulonéph 
nie proliferative diffuse lupique se fixe également au HS La reaction 
croisée des anticorps anti ADN a ete confirmée par la démonstration de 
la fixation au HS de 17 à 42 anticorps monoclonaux (AMC) anti ADN, 
Il des 17 AMC positifs se fixaient au proteoglycan de HS (PGHS) 
extrait de la membrane basale glomerulaire (MBG) humaine et 7 des 42 
AMC se fixaient directement sur des anses isolées de MBG humaine La 
liaison a HS, à PGHS et a MBG pouvait être inhibée par l'ADN de 
maniere dose-dependante Au cours de l'analyse rétrospective de 10 
patients atteints de LED en utilisant 6 à 16 serums par patient, au cours 
de 5 episodes d'exacerbât ίο η ou d'installation de la néphrite lupique, 
nous avons observe une activité anti HS dans le serum, précédant Γ celo 
Sion de la nephrite Au cours de quatre épisodes d'installation ou d'exa 
cerbalion de manifestations extrarenales du LED, l'activité anti HS n'a 
eie détectée qu une seule fois Nous postulons que la fixation des anti-
corps anti ADN au HS de la MBG peul constituer un événement immu-
nopathologique important dans le développement de la nephrite lupique 
Mots clés Anticorps anti ADN — nephrite lupique — reactivite croi 
see — sulfate d'heparan — proteoglycan — membrane 
basale glomerulaire 
Studies of Stemman [29] have shown that there is, like in 
normal subjects, no free DNA in the circulation of patients 
with active SLE nephritis Other studies claiming the presence 
of free DNA in the circulation of SLE patients have all been 
performed with serum samples, in which free DNA was appa-
rently generated during clotting [28] Also, when DNA is admi-
nistered to SLE-mice with circulating anti-DNA antibodies, it 
is rapidly cleared from the circulation by the liver and does not 
deposit in the kidney [2, 7] Although high levels of circulating 
immune complexes have been reported regularly in SLE 
patients [21, 23], there is no good evidence for the presence of 
specific DNA-anti-DNA complexes Izuietal [15], using four 
different radioimmunoassays, were unable to detect substantial 
amounts of such complexes in SLE sera This study confirmed 
a previous study in which it has been shown that anti-DNA 
binding of SLE sera did not increase after DNAse treatment, 
indicating that there was no DNA bound to anti-DNA antibo 
dies [14] In experimental animals, preformed DNA-anti-DNA 
complexes injected intravenously are rapidly cleared from the 
circulation mainly via the liver and do not localize in the kid 
ney [7] Furthermore, we and others have shown that the level 
of immune complexes in SLE sera is overestimated if the Raji 
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cell assay is used, since anti-DNA antibodies can bind directly 
to the cell membrane of Raji-cells [10, 26, 32]. Most remar­
kably, the contention that DNA anti-DNA complexes are res­
ponsible for the development of SLE glomerulonephritis, is 
generally accepted without the physical isolation of DNA from 
diseased glomeruli. The only identification of DNA in SLE 
kidneys comes from immunofluorescence studies on kidney 
sections of SLE patients or mice, in which anti-DNA antibo­
dies were used as probes [17, 20J. However, positive staining 
was only observed after treatment of tissue sections with buf­
fers containing high salt concentrations. In these studies it was 
not excluded that DNA was released from cells by the high salt 
condition. Taken together, the experiments cited above suggest 
that the presumed presence of DNA in the circulation, in circu­
lating immune complexes, or in the glomerular lesions in SLb 
patients is highly questionable. Therefore, crucial elements to 
support the concept of the pathogenicity of DNA anti-DNA 
complexes in SLb nephritis are noticeably lacking. 
More recently, the pathogenic role of DNA anti-DNA 
deposition in SLE nephritis has been challenged [6], mainly 
based on studies which show that anti-DNA antibodies can 
crossreact with several molecules. In this article we will review 
some of our published [9, 11, 12, 27] and recent data with 
regard to the crossreactivity of monoclonal and polyclonal 
anti-DNA antibodies with heparan sulfate (HS), the glycosa-
minoglycan side-chain of heparan sulfate proteoglycan 
(HSPG), which is a constituent of the glomerular basement 
membrane (GBM). 
BINDING OF HUMAN AND MURINE SLE-SERA 
TO HEPARAN SULFATE 
The first indication that anti-DNA antibodies could cross-
react with heparan sulfate (HS) was obtained when we tested 
33 human SLE sera, which were selected for their high dsDNA 
binding activity in the Farr assay or Crithidia lucihae immuno­
fluorescence test [12]. Thirty of these 33 sera bound in an 
ELISA to HS, which was purified from bovine kidney (com­
mercially obtained from Seikaguku Kogyo Ltd, Tokyo, Japan). 
The HS used was not contaminated with other glycosami-
noglycans as assessed by cellulose-acetate electrophoresis. The 
binding was not due to contaminating DNA, since extensive 
treatment of the HS preparation with DNAsel did not 
influence the binding of these SLE sera Analogous results were 
obtained with sera from 4-6 months old MRL/1 mice. Control 
experiments with normal human (n=40) or mouse sera 
(n=40), sera from patients with rheumatoid arthritis (n = 8), 
sera from patients with primary glomerulonephritis (minimal 
lesions (n = 3), focal glomerulosclerosis (n = 2), membranous 
glomerulonephritis (n=4), IgA nephropathy (n = 3)), or sera 
from patients with secondary, non-SLE glomerulonephritis 
(Wegener's disease (n = 12), Schonlein-Henoch purpura (n = 5), 
periarteritis nodosa (n=4)), did not reveal any reactivity in the 
anti-HS ELISA. The binding of the SLE and MRL/1 sera to 
HS was due to cross-reactivity of anti-DNA antibodies in these 
sera since DNA could inhibit their binding to HS, and HS 
could also inhibit, although to a lesser and more variable extent 
this binding to DNA fiable I). The latter finding indicates that 
not all anti-DNA antibodies cross-react with HS, which was 
further substantiated by our studies with monoclonal anti-
DNA antibodies as discussed in the following section. 
The potential clinical relevance of the crossreactivity of 
anti-DNA antibodies with HS can be derived from the fact that 
Table 1. Percentage of maximal inhibition by DNA or heparan sulfate 
on subsequent binding of various SLE sera (o UNA or heparan sulfate 
Coaled anngen 
Fluid pha.se inhibilor' 
S L E serum 1" 
» 2 
» 3 
» 4 
» 5 
MRL/1 serum pool 
DNA 
DNA 
98 
92 
80 
28 
59 
ВО 
Heparan 
sulfate 
90 
94 
36 
23 
45 
80 
Heparan sulfaie 
DNA 
88 
99 
70 
60 
71 
90 
Heparan 
sultalc 
76 
95 
82 
80 
86 
74 
1
 Amoum of inhibitor per well, 10 μ.% 
1
 In a dilution giving 75 Щ of the maximal ELISA signal 
Fig 1: Reaction pattern in ELISA of IgG, eluted from a human SLE 
kidney, «uh DNA (*-*) and heparan sulfate (•-•) and of 
IgG eluted from MRL/1 kidneys with DNA (·-·) and heparan 
sulfate (•-•). Control experiments were performed with IgG 
eluted from BALB/c kidneys, normal human kidneys, or kid­
neys from rats with experimental Heymann's nephritis on 
DNA ( o - o ) and heparan sulfate (C-CJ) The results are 
expressed as the absorption at 450 nm, (A450) (Reproduced 
from The Journal of Clinical Investigation 1986, 77 1824 
(ref 12) by copyright permission of the American Society for 
Clinical Investigation) 
antibodies eluted from human or MRL/1-mouse kidneys with 
a diffuse proliferative SLE nephritis did nol only bind to 
DNA, as expected, but also to a comparable extent to HS (Fig. 
1). The binding to HS could be inhibited by DNA, which indi­
cates that eluted anti-DNA antibodies were responsible for the 
binding to HS. Apparently, antibodies that had bound m vivo 
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to the kidney during the development of the SLE-nephntis, 
had crossreactive properties 
BINDING 
OF MONOCLONAL ANTI-DNA ANTIBODIES 
TO HEPARAN SULFATE 
AND HEPARAN SULFATE PROTEOGLYCAN 
Since SLE sera contain autoantibodies with a broad range 
of specificities we decided to study the crossreactions of anti-
DNA with HS in more detail using monoclonal antibodies to 
DNA (mAb), which have the advantage of their monospecifi 
city These murine mAb were produced by fusion of 
SP2/0-Agl4 myeloma cells with spleen cells from mice with 
spontaneous SLE (MRL/lpr, (NZBxW)F, hybrids) or from 
mice with experimentally induced SLE (paremal-F, chronic 
graft versus host disease) [27) From these fusions 42 mAb were 
selected All 42 mAb were positive in the anti-DNA FLISA, 28 
were positive in the anti-DNA PEC assay, 25 gave a positive 
immunofluorescence on Crithidia luciliae, and 3 were positive 
in the dsDNA Farr assay As described previously by Smeenk 
et al [27], these different anti-DNA assays can be used to 
determine the relative avidity of antibodies towards DNA In 
the order of DNA-ELISA, PEG-assay, Crithidia test, and Farr 
assay anti-DNA antibodies with an increasing avidity are 
detected The mAb which we obtained, belonged either to the 
IgM(n=6) or the IgG class (IgGl n = 4,IgG2a n = 21,IgG2b 
n = ll) From these 42 mAb, 17 bound to HS m the ELISA If 
the titer in the anti DNA ELISA was expressed relative to the 
titer in the anti-HS ELISA, the following DNA/HS ratios were 
obtained for the HS crossreactive mAb <1 n = l , l-2 n = 8, 
2-3 η=4, 3-6 η = 3 These ratios indicate that 9 of the 17 mAb 
bound equally well to HS and to DNA (ratios between 0 and 
2) Whereas the remaining 8 mAb showed a higher titer to 
DNA than to HS (ratios between 2 and 6) The binding of the 
crossreacting mAb to HS could be inhibited m a dose depen­
dent manner by DNA The amounts of DNA necessary for 
50% inhibition of mAb binding to DNA or to HS were compa­
rable and did not differ more than a factor 2 There has been 
some dispute whether crossreactivity of anti-DNA antibodies 
with different molecules is a property of «bona fide» anti-
DNA antibodies with high avidity [4, 8, 24, 27] Some authors 
have attributed these crossreactions to IgM anti DNA antibo­
dies with low avidity The crossreactivity of our mAb with HS 
was certainly not restricted to low avidity IgM antibodies, since 
14 out of 17 belong to the IgG class and, as assessed by their 
positivity in the four mentioned anti-DNA assays, also high 
avidity mAb bound to HS (for instance 2 of the 3 Farr positive 
mAb) 
Since HS forms the glycosammoglycan side-chain of hepa­
ran sulfate proteoglycan (HSPG), an intrinsic constituent of 
the glomerular basement membrane (GBM), we also tested the 
reactivity of the anti-DNA mAb with HSPG purified from iso­
lated human GBM [33, 34] During the isolation of GBM an 
extensive digestion with DNAsel and RNAse was carried out 
The HSPG preparation was not contaminated by other base­
ment membrane components or chondroitm sulfate proteogly­
can, as established by ammoacid and aminosugar analysis 
DNA was not present in the HSPG preparation since it did not 
stain with ethidium bromide and did not contain desoxynbose 
nor phosphorus Our panel of anti-DNA mAb was tested in 
ELISA using this purified HSPG preparation as coated anti­
gen Eleven of the 17 HS-EL1SA positive anti-DNA mAb 
bound to HSPG Figure 2 shows an ELISA of a representative 
mAb with a positive binding to DNA, HS, and HSPG The 
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Fig 2 Binding in FUSA of a representative mouse monoclonal anti-
DNA antibody with DNA heparan sulfate (HS), heparan sul 
fate proteoglycan (HSPG) purified from human glomerular 
basement membranes (GBM), and with other GBM compo 
nenls (collagen lype IV, laminm, and flbronectin) The results 
are expressed as the absorption al 450 nm 
binding to HSPG could be inhibited by DNA DNAsel diges­
tion of the HSPG preparation prior to coating did not 
influence the binding of these mAb to HSPG Also, on Western 
blots some of the anti-DNA mAb (n = 4) bound to intact 
HSPG If, however, HS-side chains were chemically removed 
from HSPG by treatment with trifluoromethane sulfonic acid, 
yielding the HSPG-corc protein [34], no binding was observed 
anymore, neither m ELISA, nor on Western blots In ELISA, 
none of the anti-DNA mAb bound to other GBM components, 
such as laminm, flbronectin or collagen type IV 
BINDING 
OF MONOCLONAL ANTI-DNA ANTIBODIES 
TO ISOLATED HUMAN GBM-LOOPS 
To investigate whether anti-DNA mAb could bind to HS 
within the GBM, we isolated GBM-loops from human kidneys 
according to the method of Meezan [22], which includes an 
extensive DNAsel treatment The GBM-loops that we obtai­
ned were free from glomerular cells as assessed by electron 
microscopy The anionic sites within the GBM were not lost 
during the preparation, since canonic ferritin still bound 
strongly along the GBM HS was at least in part responsible for 
these anionic sites, since the binding of canonic ferritin was 
reduced after treatment of the GBM-loops with hepantinase 
The human GBM loops were incubated with our panel of anti-
DNA mAb Seven of 42 mAb showed a discrete granular stai­
ning of the GBM This GBM-bindmg could be inhibited by 
DNA The presence of DNA on these GBM-loops was exclu­
ded with the same techniques as used for measurement of 
DNA contamination of human GBM HSPG An even stronger 
argument against the presence of DNA on these GBM loops is 
the fact that certain high avidity anti-DNA mAb did not bind 
to the GBM, which would have occurred if DNA had been pre­
sent Anionic sites within the GBM seemed to be involved in 
the binding of positive anti-DNA mAb, since preincubation of 
the GBM loops with canonic ferritin almost completely inhibí 
ted the subsequent binding of mAb, whereas preincubation 
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Table II Binding of various anti DNA mAb to GBM loops after pre 
treatment of the loops with hcparmitase (H ase) or after preincubation 
of GBM loops with calióme (CaF) or native ferritin (NF) 
mAb 
Antl DNA 36 
Anti DNA 51 
Anti DNA 29 
Anti HSPO 
core protein 
Direct 
binding 
4 + 
3 + 
2 + 
2 + 
Rinding after preincubation with 
Hase 
2 + 
1 2 + 
1 + 
2 + 
Cab 
0-1 + 
1 + 
0 
2 + 
ΝΓ 
4 + 
N D ' 
2 + 
2 + 
Binding scored semiquantttattvely on a scale nom 0 4 * 
1
 ND = not determined 
with native ferritin had no influence Pretreatment of the 
loops with hepantinase decreased, but did not abolish, the bin­
ding of anti-DNA mAb The binding of a control mAb direc­
ted against epitopes on the HSPG core protein was not 
influenced by any of these treatments (Table II) We could 
show that the hepantinase treatment of the GBM-loops did 
not lead to a complete disappearance of HS from the GBM 
(30% still remained) The remaining HS might be responsible 
for the residual anti-DNA binding but the result might also 
indicate that other anionic sites than HS within the GBM can 
serve as binding sites for anti-DNA The direct binding of anti-
DNA mAb to the GBM was not due to a non-specific charge-
interaction since none of several non-related mAb with a high 
isoelectric point ( > 9 0) bound to the GBM A preliminary 
indication that binding to the GBM can also take place m vivo, 
can be derived from the following experiment Normal 
BALB/c mice were inoculated intrapentoneally with 2 χ IO6 
anti-DNA mAb producing hybndoma cells After 2-3 weeks, 
these animals were sacrificed and their kidneys were studied 
with indirect immunofluorescence The kidneys of mice inocu­
lated with hybndomas which produced anti-DNA mAb that 
did not bind to the GBM m vitro showed only mesangial depo­
sition of immunoglobulins within the glomerulus By contrast, 
kidneys from mice inoculated with hybndomas which produ­
ced anti-DNA that bound to the GBM m vitro showed also 
granular deposition of immunoglobulins along the capillary 
wall It remains to be investigated whether these latter mice 
will also develop proteinuria and/or proliferative glomerulo­
nephritis 
ANTIBODIES AGAINST HEPARAN SULFATE 
IN SERA FROM PATIENTS 
WITH RENAL OR NON-RENAL 
SLE MANIFESTATIONS 
In order to see whether the crossreactivity of anti-DNA 
antibodies with HS had any clinical relevance, we studied 
retrospectively sera from 10 SLE patients For each patient 
6-16 serum samples obtained at various time points during the 
disease were analyzed (under code) in the Fan-assay, anli-
DNA ELISA and anti-HS LI ISA All 10 patients fulfilled the 
revised ARA criteria for SLE [31] In 4 patients a biopsy-
proven diffuse proliferative SLE nephritis had developed, and 
one of these patients experienced later on an acute exacerba 
lion of nephritis During the period of serum collection, 4 epi­
sodes of non-renal manifestations occurred (one cerebral SLE 
manifestation, one episode of severe leuko- and thombocyto-
penia, one episode of arthritis, and one episode of vasculitis) 
Three patients remained clinically stable during the study In 
all 5 episodes of onset or exacerbation of nephritis we found, 
Table III Relation between SLF disease acttvilv and presence of 
anti HS activity in serum of SLE patients 
Disease activity 
Onset 'cxaLerbation 
nephritis (episodes) 
Onset/exai-erbation 
non renal manifes 
lanon (episodes) 
Clinically stable 
(patients) 
Number of episodes 
or patienis 
4 
3 
Number of episodes 
or patienis positive 
in anti HS ELISA 
5 
1 
0 
*-\ -a- DNA Ebu 
• HS Ebsa 
•·' Fan ааму 
'i • AWW 
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day· 
Fig 3 Antibody profile in one of the SLE patients studied The hort 
zonta) axis represents a time scale in which day 0 is the timc-
point at which the first studied serum, was obtained The 
moment of development of nephritis is indicated by an arrow, 
the moment of onset of the non renal manifestation by a dia­
mond On the vertical axis the titers measured m the various 
assays are given as log units of activity A value of 0 6 or lower 
should be regarded as negative The titer in both ELISA was 
defined as the reciprocal dilution of the sample giving an 
aborption of 1 0 at 450 nm In the Farr assay the titer is 
expressed as units/ml, 1 U is defined as the dilution of ami 
dsDNA that bind 304Ό of the input DNA (100 ng) 
prior to the onset, a positive binding in Ihe anti-HS ELISA, 
coinciding with a rising anti-DNA titer in both the Farr-assay 
and the anti-DNA ELISA After increase of immunosuppres­
sive treatment in these patients we found a decrease in anti-
DNA titer, while the anti HS ELISA became negative In the 
four episodes of non-renal manifestations, the anti-DNA titer 
rose in all 4 cases, but only in one episode (leuko- and throm­
bocytopenia), a positive antt-HS Ы ISA was found Anti-HS 
activity was never detectable in any of the sera from the three 
patients, who remained clinically stable Table III summarizes 
the results obtained in this preliminary study Figure 3 shows 
an example of the antibody profile that we obtained in one of 
the patients Prior to the development of the nephritis (indica­
ted with an arrow) a rising titer was found in all 3 assays After 
increase of immunosuppressive treatment, the anti-DNA titer 
declined and the anti-HS titer became negative At day 500, 
rising titers in both the Farr assay and the anti-DNA ELISA 
were seen, while the anti-HS titer remained negative At day 
580 (indicated with a diamond) the patient developed a vascu­
litis of the skin This profile, together with those observed in 
the other patients, indicates that posiltvity in the anti-HS 
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ELISA is not a mere reflection of a high anti-DNA titer but it 
suggests that in certain situations a subpopulation of anti-
DNA antibodies is formed which crossreact with HS 
Although these observations have to be extended and should 
be carried out prospectively, they seem to suggest that (here is 
an association between the presence of anti-HS antibodies in 
the serum and the onset of SLE nephritis 
DISCUSSION 
The studies presented in this paper show that both mono­
clonal and polyclonal ami-DNA antibodies can crossreact with 
HS This crossreauion with HS is not unique since it has been 
reported that ami-DNA antibodies can crossreact with several 
other molecules such as phospholipids [18, 2SJ, cell-surface 
proteins of different cell types [16], and cytoskeletal proteins 
|1] Based on these studies, anti DNA antibodies have been 
divided in antibodies reactive with nucleotide or nucleotide 
sequences and antibodies reactive with the sugar phosphate 
backbone of DNA The latter are thought to be responsible for 
crossreactive binding to various molecules [5] It has been pro­
posed that the crossreactive targets are phosphodiestcr linked 
phosphate groups comparable to those in the backbone of 
DNA [19, 25) However, we conclude, from our studies with 
glycosarmnoglycans [9, 11, 12], that also molecules with other 
repeating anionic sites such as sulfates can serve as crossreac­
tive moieties This crossreactivity of anti-DNA antibodies 
sheds new light on the diversity of serological abnormalities in 
SLE, since the great variety of apparently unrelated antibodies 
may be due to anti-DNA antibodies reacting with different 
antigens which share cross reactive epitopes 
Furthermore, the crossreacttons of anti DNA with HS 
might have implications for the immunopathologtcal events 
that take place in SLE nephritis The development of SLE 
nephritis and proteinuria may be caused by binding of anti-
DNA antibodies to HS within the GBM This glycosaminogly-
can side-chain of HSPG is predominantly responsible for the 
negative charge of the GBM and the charge-selective permeabi­
lity of the GBM [13] Reduction or neutralization of heparan 
sulfate in the GBM leads to proteinuria in experimental ani­
mals [3, 13] A reduction of HS associated polyaniomc sites 
has also been held responsible for proteinuria in congenital 
nephrotic syndrome (35] Our hypothesis of the direct binding 
of anti-DNA antibodies to the GBM, is supported by both the 
m vivo studies, in which we found GBM localization of arti-
DNA antibodies after ι ρ inoculation of hybndoma cells, and 
by the reactivity of eluted antibodies from kidneys with SLE 
nephritis We hypothesize that binding of anti DNA antibo­
dies to the HS-associaied polyaniomc sues in the GBM might 
be an important event in the development of SLE nephritis, 
either by interference with physiological functions, such as per­
meability, and/or by triggering inflammatory reactions locally 
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NOTE ADDED IN PROOF 
Recent experiments have indicated that anti DNA mAb bind to 
HS and HSPG via bound DNA/hislon complexes A similar mecha­
nism for monoclonal ami DNA binding to cell surfaces has been des­
cribed recently by Jacob el ol (Рта. Natl Acad Sci USA 86 4669-4673, 
1989) Whether this is also true for polyclonal ami DNA reaciivity 
with HS is currently under invesligation 
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To study in more detail the cross-reactive binding of anti-DNA antibodies 
to heparan sulfate (HS) and heparan sulfate proteoglycan (HSPG) purified 
from glomerular basement membranes (GBM), the binding pattern of 31 
murine IgG anti-DNA MoAbs, derived from MRL//pr, NZB/W and graft-
versus-host diseased mice, was analysed. In ELISA we found binding of 10 
anti-DNA MoAbs to HS. Seven of the 10 anti-HS positive clones bound to 
HSPG but not to the HSPG core protein in ELISA and/or on Western blots. 
However, DNase-I treatment partly reduced this binding, whereas after 
purification of Mo Ab by protein-A sepharose chromatography under dis­
sociative conditions, all clones completely lost their binding capacity to HS 
and HSPG. Culturing of hybridoma cells in the presence of'H-thymidine 
revealed DNA bound to the MoAb. Although the binding to HS and HSPG 
could be reconstituted by the addition of the protein-Α column effluent, 
this was not possible by the addition of DNA alone. Therefore, we per­
formed immunoprecipitation of the effluent with purified MoAb and 
subsequent SDS-PAGE which showed that the complex also contained 
histones. However, histones alone were also not able to reconstitute the 
binding to HS and HSPG. It is concluded that binding of anti-DNA MoAb 
to HS and GBM-HSPG is mediated via bound complexes containing both 
DNA and histones. A comparable reaction with polyclonal anti-DNA Ab 
might play a role in the pathogenesis of SLE nephritis, since histones have 
a very high affinity for HS, the major glycosaminoglycan of the GBM. 
Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by 
antibodies reacting with a great variety of autoantigens [1] Antibodies directed 
against dsDNA are considered the major serological marker for this disease [2] SLE 
is generally regarded as an immune complex-mediated disease, m which deposition 
of DNA/anti-DNA immune complexes from the circulation arc held responsible for 
the development of the various disease manifestations In this concept, deposition of 
immune complexes m the glomeruli leads to the onset of nephritis [3] Several studies 
have shown an association of high levels of anti-DNA antibodies in the serum with 
the development of SLE nephritis High affinity anti-DNA antibodies have also been 
demonstrated in eluates from kidneys of patients with active SLE nephritis [4—6] 
However, the precise nature and composition of the antigen bound to anti-DNA in 
the circulation or in glomerular deposits has been a matter of much debate and 
controversy In a recent review, Fourme [7] postulates that not DNA, but DNA 
bound to nuclear proteins, could play a role m the pathogenesis of SLE 
An alternative explanation for the pathogenicity of anti-DNA in SLE nephritis has 
been proposed, based on studies which showed that anti-DNA antibodies can cross-
react with several other molecules [8-10], especially phospholipids [11,12], glycos-
aminoglycan side-chains of proteoglycans [9, 10, 13], cell-surface proteins [14] 
and different cell types [15, 16] In this concept SLE nephritis is caused by direct, 
cross-reactive binding of anti-DNA to epitopes present within the glomerulus or 
GBM [8-10, 17-19] We have previously shown [9, 10] that polyclonal anti-DNA 
antibodies can bind to HS, the glycosaminoglycan side chain of HSPG, which is an 
intrinsic constituent of the GBM This HSPG is the major proteoglycan of the GBM 
and is responsible for the negative charge of the GBM and its charge-selective 
permeability [20-22] 
The analysis of the characteristics of cross-reacting anti-DNA antibodies by using 
SLE sera is hampered by the polyclonal nature and the broad specificity of the 
autoantibodies present in these sera We decided, therefore, to use monoclonal anti-
DNA antibodies to study in more detail the cross-reactive binding with HS and 
HSPG In this paper we present the reactivity of 31 IgG anti-DNA MoAbs with HS 
and HSPG isolated from human GBM Only MoAbs of the IgG class were studied 
since it has been claimed that several cross-reactions of anti-DNA are mainly 
observed with IgM antibodies of low avidity, which are not true representatives of 
the pathogenic anti-DNA antibodies found in SLE patients [23] 
Based on our previous findings that cross-reactive binding of anti-DNA was 
influenced by nuclear constituents released from hybndoma cells complexed to anti-
DNA [24], the influence on cross-reactivity with HS and HSPG of DNase treatment 
and purification of MoAb under dissociative conditions was analysed 
Materials and methods 
Production of monoclonal antibodies (MoAbs) to DNA 
Monoclonal antibodies to dsDNA were produced as described previously [25] 
Briefly, spleen cells from mice with spontaneous ((NZB χ W)F,, MRL//pr) or experi­
mentally induced SLE-hke disease (mice with a parental-F, chronic GVH disease), 
30 
that produced high titers of anti-dsDNA, as detected in the Crithidia luciliae or 
the Farr assay, were fused with the murine myeloma cell line SP2/0-Agl4 in 4 2 0 0 
PEG (Koch-Light Labs, Colnbrook, UK). The isotype of the MoAb was determined 
in an isotype-specific ELISA as described previously [26] and in some cases in 
an Ouchterlony assay using subclass-specific antibodies (Nordic, Tilburg, The 
Netherlands). Only MoAbs of the IgG isotype were selected for further studies. 
The concentration of Ig in the different MoAb preparations was determined by 
radial immunodiffusion using subclass-specific antisera (Nordic, Tilburg, The 
Netherlands). 
Purification of MoAb 
DNase treatment 
Supernatants from anti-DNA producing hybridomas were incubated for 1 h at 37CC 
with DNase-I (Boehringer, Mannheim, FRG) at a final concentration of 40 μg/ml 
and 10 т м MgCl2. To quench the reaction, EDTA (Merck, Darmstadt, FRG) at a 
final concentration of 1 5 т м was added. Control supernatants were treated in a 
comparable manner with buffer not containing DNase-I. 
Affinity-chromatography 
Monoclonal antibodies were purified from supernatants after concentration on an 
Amicon YM 30 filter, or from a 50 0 0 ammonium sulfate precipitate of ascites pro­
duced in BALB/c mice. Concentrated MoAb solutions were diluted in buffer to a 
final concentration of 3 м NaCl, 1.5 M glycine-NaOH, pH 8.9 (binding buffer) and 
subsequently applied to a protein-Α sepharose column (Pharmacia, Sweden) equi­
librated in binding buffer. Bound immunoglobulins were eluted with a solution of 
0.1 M citric acid and a pH gradient ranging from 4 to 6, depending on the isotype to be 
eluted. Eluate was dialyzed against PBS and stored at — 20oC. In the experiments in 
which purified MoAb were reconstituted with the protein-A column effluent, the 
high salt concentration of the effluent was removed by dilution with a 20-fold greater 
volume of PBS and subsequent concentration, by ultrafiltration on an Amicon YM 5 
filter, to the original volume of the concentrated supernatant that had been applied to 
the column. The column effluent did not contain Ig, as checked by radial immuno­
diffusion, or anti-DNA, anti-HS, anti-HSPG, or ANA reactivity as assessed in the 
various assays (see below). 
Tests for antibody specificity 
ANA 
Antinuclear antibody reactivity was determined with an indirect immunofluor­
escence test on rat liver slides [27]. 
Anti-dsDNA antibody assays 
Anti-dsDNA antibody activity was determined in different assays as described pre­
viously: anti-dsDNA ELISA [9], the immunofluorescence test (IFT) on Crithidia 
luciliae [28], Farr assay [28], and PEG assay [29]. Relative anti-DNA avidity was 
31 
analysed by the reactivity of the MoAb in the different anti-DNA assays (anti-DNA 
ELISA, PEG assay, I F T on Crithtdia and Farr assay), as described previously [25]. 
Anti-HS ELISA 
HS purified from bovine kidney was purchased from Seikaguku Kogyo Ltd. (Tokyo, 
Japan) and the anti-HS ELISA was carried out as previously described [9]. The 
cross-reactivity of a MoAb with HS was expressed as the ratio between the titers of 
the MoAb in the anti-HS ELISA and anti-DNA ELISA. The titer in both ELISAs 
was defined as the reciprocal dilution of the sample giving an absorption of 1.0 at 
450 nm. Both titers were corrected for non-specific binding to protamine by 
measuring absorbance using PBS instead of antigen after precoating with protamine. 
This ratio was determined for all MoAbs before and after DNase treatment of the 
supernatants. 
Anti-HSPG ELISA 
H SPG was isolated from human kidneys as described previously [30]. Analysis of the 
purified H SPG preparation for amino acid and amino sugar composition revealed no 
contamination with collagen or chondroitin sulfate proteoglycans, since hydroxy-
proline, hydroxylysine and galactosamine were not detectable. Contamination of the 
HSPG preparation with DNA was excluded in several ways [31-33]. Furthermore, 
treatment of the purified HSPG with DNase-I prior to coating did not influence the 
binding characteristics of MoAb to HSPG. The core protein of HSPG was obtained 
by treating the HSPG with trifluoromethanesulfonic acid (TFMS, Merck, 
Darmstadt, FRG) [34]. The anti-HSPG ELISA was carried out as described 
previously [30]. 
Anti-GBM components ELISA 
Polystyrene microliter plates (Greiner) were coated overnight at room temperature 
with 100 μΐ/well of 10 μg/ml mouse-laminin (Sigma) or human-fibronectin (Sigma) 
in coating buffer (10 т м Tris-HCL, pH 7.4), or human collagen type IV (Sigma) in 
PBS. Thereafter, the ELISA was carried out as described for the anti-HSPG 
ELISA. Positive controls were: a rabbit anti-mouse laminin antiserum (diluted 1:50 
in PBS), an anti-collagen IV MoAb (undiluted supernatant), and an anti-human 
fibronectin MoAb (Sigma, diluted 1:25 in PBS). 
In all ELISA assays MoAbs were also tested on wells in which during the coating 
procedure buffer without antigen was used. 
Western blotting on intact HSPG and HSPG core-protein 
This was carried out as described previously [30]. As a positive control a MoAb 
against human GBM-HSPG, which recognizes an epitope present on the core 
protein of HSPG was used. In the anti-HSPG ELISA and Western blotting, 
positive clones were also tested after DNase treatment and after purification under 
dissociating conditions. 
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Immunoprecipitatwn with purified Mo Ab 
To 200 μΐ prc-swollen protein-A sepharose CL4B beads (Pharmacia, Sweden) 1 mg 
of purified MoAb was allowed to bind during constant rotation for 3 h at room 
temperature Beads with bound Ig were washed three times with PBS, subsequently 
incubated overnight with column effluent (from the purification procedure) at 4 С 
and washed again three times with PBS. Finally beads were diluted 1:1 in sample 
buffer containing 10°,, B-mercapto-ethanol and run in a IO0,, SDS-PAGE gel [35]. 
Isolation of ^H-thymidine labeled immune complexes 
Hybndoma cultures were grown at cell densities of 2.5 χ IO5 cells/ml. To these 
cultures, 0 5 μ Ο 'H-thymidine'lO5 cells were added and allowed to grow for 3 days. 
Produced IgG was isolated, by adding 200 μΐ pre-swollen protein-A sepharose beads 
to 10 ml of culture supernatant, and incubated for 3 h at room temperature There­
after these beads were washed three times with PBS and after addition of 10 ml of 
scintillation mixture (Aqua Lumen Plus, Lumac bv., The Netherlands), counted for 
radioactivity 
A panel of non-related MoAb was used as a negative control in all assays. 
Results 
Characteristics of anti-DNA MoAb 
From several fusion experiments 31 MoAbs of the IgG class were selected. All 31 
MoAbs were positive in the anti-DNA ELISA, whereas 24 were positive in the PEG 
assay, 20 positive in the Cnthidia assay and five positive in the Farr assay. As postu­
lated previously [25], these four anti-DNA assays detect anti-dsDNA antibodies of 
different avidity towards dsDNA. In the Farr assay only high avidity antibodies are 
detected, whereas in the other assays such as Cnthidia, PEG and ELISA both high 
avidity antibodies and antibodies with lower avidity are detected. According to the 
anti-DNA assay behaviour, our panel represents a spectrum of anti-DNA with 
varying avidities since 1 MoAb is of low avidity (only ELISA positive), 26 MoAbs 
have intermediate avidity (ELISA and PEG and/or Cnthidia positive) and five 
MoAbs have high avidity (Farr positive). These differences in avidity were not 
associated with a particular IgG isotype or MoAb origin. Furthermore, the majority 
of the MoAb obtained were of the IgG2a(n = 21)or IgG2b(« = 8) subclass. 
Reactivity of anti-DNA MoAb culture supernatants with HS and HSPG 
When these MoAbs were tested in the anti-HS ELISA, 22 out of 31 bound to HS. 
However, the titer in the anti-HS ELISA varied considerably. In order to express the 
relative cross-reactivity of the MoAb we calculated the HS; DNA binding ratio from 
the titers towards HS and DNA. The MoAbs with an HS 'DNA binding ratio > 0.20 
were considered as cross-reactive (w= 10), and the characteristics of these clones are 
summarized in Table 1 Since HS is present in vivo as the glycosaminoglycan side 
chain of HSPG, the reactivity of our panel of IgG anti-DNA MoAb was also tested in 
ELISA with HSPG (purified from human GBM) as coated antigen. A representative 
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Table 1. Anti-DNA binding characteristics of the anti-DNA clones (crude culture 
supernatants) which cross-react with H Sim ELI S A (HSjDNA ratio >0.20) and their 
binding to HSPG in ELISA and on immunoblots 
JtClone 
2 
3 
6 
7 
23 
32 
34 
42 
46 
51 
Subclass 
IgG2b 
IgG2b 
IgG2b 
IgG2b 
IgG2a 
IgG2a 
IgG2a 
IgG2a 
IgG2a 
IgG2a 
ELISA 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Anti-DNA assay 
PEG 
+ 
+ 
-
+ 
+ 
— 
+ 
— 
+ 
Crithidia 
— 
— 
+ 
+ 
-
-
+ 
+ 
+ 
Farr 
— 
— 
— 
— 
+ 
+ 
+ 
— 
— 
Anti-HSPG assay 
ELISA 
+ 
+ 
+ 
— 
— 
+ 
+ 
+ 
— 
+ 
Immunoblot 
+ 
+ 
+ 
-
— 
+ 
— 
— 
— 
— 
100 
Figure 1. Representative example of reartivity in ELISA of an anti-DNA MoAb (clone #32) with 
HSPG (O), with the core protein of HSPG (x) or with other glomerular basement membrane 
components (laminin, collagen type IV, fibronectin) and m a control ELISA (Δ ). 
example of binding of MoAb to HSPG is shown in Figure 1. In this anti-HSPG 
ELISA seven clones (all positive in the anti-HS ELISA) were positive (Table 1). 
Reactivity against the HSPG core protein or against other GBM components such as 
fibronectin, laminin and collagen type IV was absent for all the 31 anti-DNA clones 
(Figure 1). From the seven clones which were reactive in the anti-HSPG ELISA, 
four showed binding on Western blots to intact HSPG (Figure 2), whereas none of 
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Figure 2. Western blots on HSPG, punned from human GBM (left 2 lanes) and on HSPG core protein 
(right 2 lanes) Lane 1, positive control, a MoAb against human GBM-HSPG. Lane 2, an anti-DNA 
MoAb (clone #32) 
the anti-HSPG ELISA negative clones bound. The staining pattern in the Western 
blot was identical to that observed with the positive control, a MoAb against human 
GBM-HSPG. After chemical removal of the negatively charged HS chains, none of 
the anti-DNA clones showed binding to the core protein, whereas the control MoAb 
still bound to epitopes present on the core protein of HSPG (Figure 2). These 
findings on Western blots confirm the ELI SA results showing that anti-DNA MoAb 
can bind to intact HSPG purified from the human GBM and that they react with 
epitopes within the HS side chains of GBM HSPG. 
Reactivity of anti-DNA MoAb with HS and HSPG after DNase treatment 
Recently, we found that DNA/anti-DNA complexes, present in culture super­
na tan ts, can considerably influence the cross-reactive binding patterns of anti-DNA 
35 
2 3 6 7 23 32 34 42 46 51 
Clone number 
Figure 3. HS DNA binding ratio for the various cross-reactive clones before and after DNase treat­
ment The HS DNA binding ratio was calculated by dividing the titer in the anti-HS ELISA by the titer 
in the anti-DNA ELI SA, corrected for the binding in the protamine-coated control ELI S A. Those MoAb 
with a ratio > 0.20 were regarded as cross-reactive. •, before DNase; Ά, after DNase. 
MoAb [24]. To circumvent this, we also studied binding of our MoAb to HS after 
DNase-I treatment. In Figure 3 (hatched bars) the HS/DNA binding ratios are 
shown after DNase treatment for those clones, which has an HS 'DNA binding ratio 
> 0.20 before DNase treatment. Seven clones still had a ratio > 0.20 after DNase 
treatment, but three clones lost their cross-reactivity with HS after DNase treatment 
(ratio shifted from >0.20 to <0.01). Of the seven clones that were positive in the 
HSPG ELISA before DNase treatment, the binding of five clones was strongly 
reduced after DNase digestion of the crude culture supernatant (residual binding 
< 45 0 о ). Also, on the Western blots we observed that two of the four positive clones 
(£2 and Í6) showed a reduced binding to HSPG after DNase treatment (Table 2). 
Thus, in the anti-HS ELISA, the HSPG ELISA, and in the Western blot on 
HSPG, binding of DNase-sensitive material to anti-DNA MoAb is at least in part 
responsible for cross-reactive binding of anti-DNA to HS and HSPG. 
Reactivity with HS and HSPG of anti-DNA MoAb purified under dissociating 
conditions 
To investigate whether the residual binding after DNase treatment to HS and HSPG 
was caused by insufficient removal of nuclear constituents by DNase digestion, we 
also studied binding to HS and HSPG after purification of the MoAb on protein-A 
sepharose under dissociating conditions. During this purification nuclear con-
stituents bound to the MoAb will dissociate and be released in the column effluent. 
After this procedure all MoAbs previously positive in the anti-HS ELISA became 
negative, whereas they all showed unaltered ANA reactivity. The reactivity with HS 
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Table 2. Cross-reactivity of anti-DNA with GBM H SPG in ELISA andón Western 
blots 
fClone 
2 
3 
6 
32 
34 
42 
51 
Percentage residual 
binding in 
+ DNase' 
14 
120 
31 
100 
55 
0 
0 
ELISA' 
Purified4 
0 
0 
0 
0 
0 
0 
0 
-DNase 
3 + 
2 + 
4 + 
4 + 
neg 
neg 
neg 
Staining intensity on 
HSPG blot2 
5
 + DNase 
1 + 
2 + 
1 + 
4 + 
neg 
ND 
ND 
Purified 
neg 
neg 
neg 
neg 
ND 
ND 
neg 
'Percentage residual binding is based on ELI SA titers before and after DNase treatment, and before and 
after purification under dissociative conditions 
2Scored semiquantitatively on a score from 0 to 4 + 
' + DNase culture supernatant treated w ith DNase-I 
'Purified under dissociating conditions (3 M salt) on a Protein A Sepharose column 
5
 — DNase reactivity of crude culture supernatant before DNase-I treatment 
Figure 4 Reactivity of clone Ï32 in the HSPG ELISA before purification ( О ), after purification under 
dissociative conditions on a protein-Α sepharose column ( Δ ) and after addition of the protcin-A column 
effluent to the purified MoAb ( ' ) 
could be restored by addition of protein-Α column effluent t o the purified MoAb 
(data not shown). After purification the binding to HSPG was also abrogated for all 
clones; Figure 4 shows a representative experiment with clone £32. After purification 
of the MoAb under dissociating conditions this clone completely lost its binding 
capacity to HSPG, while tested in the same immunoglobulin concentration as the 
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Figure 5. SDS-PAGE analysis of protein-Α column effluent. The material was immunoprecipitated 
with a purified anti-DNA MoAb (lane 3) or a non-related control MoAb (lane 4). For comparison lane 1 
was loaded with BSA and lane 2 with calf thymus histones. 
original culture supernatant. However, binding to H SPG was entirely reconstituted 
through addition of protein-Α column effluent. Also on Western blots, MoAb no 
longer bound after purification (Table 2). These findings demonstrate that after 
dissociation of antigen bound to anti-DNA MoAb, the binding to HS and HSPG is 
lost. 
Characterization of antigen-antibody complex responsible f or cross-reactivity with HS 
and HSPG 
As mentioned above, the binding of certain purified MoAbs to HSPG was restored 
by addition of the protein-Α column effluent. The composition of the antigen 
complex present in the protein-Α column effluent which could reconstitute MoAb 
binding to HSPG was analysed with immunoprecipitation using purified anti-DNA 
MoAb and subsequent SDS-PAGE. As shown in Figure 5 the precipitated material 
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clearly shows multiple bands with a molecular weight identical to those of calf 
thymus histones (lane 3). The presence of DNA in the nuclear constituents 
complexed to MoAb was shown after hybridoma culture in the presence of 3H-
thymidine. Isolation under non-dissociating conditions of produced MoAb on 
protein-A sepharose and measurement of radioactivity revealed that H SPG cross-
reacting antibodies had bound up to 25 times more DNA than non-related MoAb 
(for example, 74,000 cpm for MoAb Ï32 compared to 2,738 cpm for a control non-
DNA MoAb). The presence of DNA in the complex bound to the MoAb was further 
substantiated by the fact that DNase treatment completely abolished the reconsti-
tutive action of the antigen complexes within the column effluent. No reconstitution 
was obtained by addition of either DNA or histones alone (concentration range 
from 0.1 to 100 μg/ml). To demonstrate that these DNA/histone complexes bound to 
the anti-DNA are responsible for the binding to HS and HSPG, we tested MoAbs 
binding to HS after purification under physiological conditions (pH7.5, 0.15 м 
NaCl) on protein A Sepharose. For the MoAb from which the culture supernatant 
bound to HS and HSPG (n = 7) the same reactivity was found after purification 
under physiological conditions. Since free DNA (see above) or histones (Figure 5 
lane 4) do not bind to protein-Α Sepharose, this means that DNA/histones are bound 
to the MoAb. This indicates that the binding to HS and HSPG is mediated via DNA/ 
histone complexes bound to anti-DNA and is not due to the binding of free histones 
and/or DNA in the crude culture supernatants with subsequent binding of the anti-
DNA MoAb. Therefore, we conclude that the binding of anti-DNA MoAb to HS or 
HSPG is mediated via bound DNA/histone complexes. 
Discussion 
We previously reported that polyclonal anti-DNA antibodies can bind to HS [9,10], 
and we assumed that binding of anti-DNA occurred directly to the anionic sites (i.e., 
sulfate and carboxyl moieties) of the HS molecule. The binding of anti-DNA to HS 
could be inhibited dose-dependently by DNA and showed an identical sensitivity to 
increasing ionic strength as the binding of anti-DNA to DNA. Based on these find­
ings, we hypothesized that direct binding of anti-DNA to HS could be involved in 
the pathogenesis of SLE nephritis. Binding to HS of anti-DNA antibodies eluted 
from human and murine SLE kidneys seemed to support this contention [9]. 
In this study MoAbs to DNA were used to study the cross-reaction with HS and 
HSPG in more detail. We found that crude culture supernatants of anti-DNA pro­
ducing hybridomas bound to HS (10 out of 31) and, more importantly, from these 10 
anti-HS positive clones seven bound to HSPG isolated from human GBM. These 
cross-reacting clones displayed various anti-DNA avidities, as determined by their 
reactivity pattern in the different anti-DNA assays [25]. Furthermore, they were of 
the IgG2a and IgG2b subclass, which are regarded as the most pathogenic in vivo 
[36]. During analysis of cross-reactive binding patterns with several molecules, we 
found that supernatants of anti-DNA-producing hybridomas contained DNA/anti-
DNA complexes, which had a profound impact on cross-reactive behaviour [24]. 
Therefore, we analysed the influence of DNase treatment on the binding of anti-
DNA MoAb to HS and HSPG. DNase digestion could only partly diminish the 
binding to HS. To investigate whether the remaining binding of anti-DNA MoAb 
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after DNase treatment to either HS or HSPG represented true cross-reactivity or 
was due to insufficient digestion of bound DNA or the presence of other nuclear 
constituents, we purified the MoAb under dissociative conditions on a protein-A 
sepharose column Under these conditions (3 м NaCl, 1 5 м glycine-NaOH, pH 8 9) 
nuclear antigens bound to anti-DNA will dissociate After this purification all MoAb 
lost their binding capacity to HS and HSPG As we have published before [24] the 
reactivity in the various anti-DNA assays also changed significantly after this purifi­
cation procedure With the exception of four clones (see below), the reactivity 
towards DNA increased after purification (mean binding, 140"(), compared to the 
binding of the crude culture supernatant) 
The discrepancy between the reactivity towards HS and HSPG after DNase-I 
treatment and after purification under dissociating conditions of the MoAb must be 
due to incomplete digestion of DNA by DNase since some anti-DNA antibodies can 
protect the bound DNA from DNase digestion [37], and furthermore to the presence 
of histones [38] 
Addition of protein-A column effluent to purified MoAb restored the binding 
to HS and HSPG, but this reconstitution was not achieved by the addition of 
DNA Analysis of material bound to MoAb revealed the presence of DNA since 
3H-thymidine DNA was present in the complex, and reconstitution with protein-A 
column effluent was abrogated by DNase treatment Besides DNA, the complex 
also contained histones because immunoprecipitation and subsequent SDS-PAGE 
clearly showed multiple bands corresponding in molecular weight to calf thymus 
histones Apparently, the binding to HS and HSPG was mediated through a DNA' 
histone complex bound to MoAb during the culture procedure, and was not due to 
direct binding of anti-DNA to HS or HSPG This was further substantiated by the 
fact that four out of seven MoAbs with positive binding to HSPG showed after 
purification a considerably higher reactivity with the histone/DNA complex in 
ELI SA than with DNA or histones alone (data not shown) Comparable results were 
recently published by Jacob et al They report that the binding of an anti-DNA 
MoAb to a certain cell-surface protein (LAMP) is not a direct binding, as suggested 
before [14], but mediated via a DNA/histone complex [39] In addition, this MoAb 
had a higher affinity for DNA/histone complexes or nucleosomes than for DNA 
Based on these data it seems justified to conclude that some of our 'cross-reacting' 
MoAbs recognize an epitope only accessible or presented if DNA is complexed with 
histones/nucleoprotems This type of antibody specificity has already been described 
in SLE patients [40] 
Elegant studies by Schmiedekc et al [41] have recently shown that histones have a 
very high affinity for the GBM. They demonstrated that after perfusion, histones 
bound to the GBM in a fine granular pattern Furthermore, it was found that these 
glomerular-bound histones could act either as a planted antigen or as a matrix for 
binding of subsequent administered DNA Kinetics and avidity of intraglomerular 
binding of various histone fractions were identical to those found in vitro for the 
various histones with hepann-sepharose, which has a great similarity to HS This 
binding had a very high affinity, since 6 м guanidine-HCl had to be used to elute these 
histones This study makes it very likely that histones can bind to HS in the glomeru­
lus Our findings underline and support these findings, since we showed that those 
MoAbs which bound to HS and HSPG dui so via a bound DNA/histone complex 
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These D N A histone complexes could be dissociated from the a n t i - D N A MoAb by 
3 M salt conditions T h i s implies that the affinity of histones for heparan sulfate in the 
G B M might be even higher than the affinity of the nucleosome for the a n t i - D N A It 
is conceivable, therefore, that the high affinity for H S of the histones within the 
nucleosomes bound to the ant i -DNA antibody strongly enhances the binding of the 
ant i-DNA antibody to the G B M 
In recent years evidence has accumulated that H S plays a pivotal role in the 
charge-selective permeability of the G B M [42] and that reduction or neutralization 
of H S in the G B M leads to proteinuria Therefore, binding of a n t i - D N A antibodies 
to H S via a D N A histone complex might be an important event in S L E nephritis 
either hy interference with physiological functions and/or by triggering inflamma­
tory reactions locally In a longitudinal study in S L E patients, we found that ant i-HS 
reactivity in S L E patients was associated with the onset of nephritis (Termaat et al 
CUn Exp Imm 1990, in press) F u r t h e r studies are necessary to define more pre­
cisely the role of nucleosomes in the pathogenesis of S L E nephritis Studies are now 
in progress to analyze whether nucleosomes or DNA/histone complexes can also 
mediate binding of our MoAb to the G B M in vivo 
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CHAPTER 4 
Anti-DNA antibodies and lupus nephritis: the complexity of 
crossreactivity. 
K. Brinkman, R.M. Termaat, J.H.M. Berden and R.J.T. Smeenk. 
Published in Immunol.Today 1990: 11, 232-234. 

It has been suggested that crossreactivity of anti-DNA antibodies 
plays a central role in the development of lupus nephritis 
Experiments with monoclonal anti-DNA antibodies initially 
seemed to sustain this intriguing hypothesis but such studies 
may easily lead to incorrect conclusions In this short article, Kees 
Brinkman and colleagues discuss the validity of these studies and 
challenge the role of crossreactivity in the pathogenesis of lupus 
nephritis 
The detection of anti double-stranded DNA (dsDNA) anti­
bodies in the circulation of patients is one of the major 
criteria for the diagnosis of systemic lupus erythematosus 
(SLE)' Moreover, exacerbations of the disease are pre­
ceded by increasing anti-DNA levels2, and the develop­
ment of lupus nephritis, one of the most serious 
complications of the disease, strongly correlates with the 
presence of high-avidity anti-DNA3 
Although these findings support the proposition that 
anti-DNA is involved in the pathogenesis of SLE, an enor­
mous amount of scientific investigation has failed to 
reveal the exact mechanism through which this occurs 
Immune complexes 
Historically, SLE was considered to be the classical 
example of an immune complex disease, anti-DNA anti­
bodies were thought to form immune complexes with 
circulating DNA, and deposition of these complexes in the 
(glomerular) basement membranes thought to initiate an 
inflammatory response4 However, it has proven difficult 
to demonstrate free DNA5 and DNA-anti-DNA immune 
complexes in the circulation of patients6, moreover, arti­
ficially injected DNA or immune complexes appear to be 
rapidly cleared through the liver, both in SLE subjects and 
in healthy individuals78 
Crossreactivity 
An alternative hypothesis challenged the original model 
during recent years it held that anti-DNA can bind directly 
to tissues as a result of crossreactivity with several anionic 
tissue constituents9 The possible relevance of anti DNA 
crossreactivity to the pathogenesis of SLE was stressed by 
the finding of a multitude of crossreactions among mono 
clonal anti-DNA antibodies During the last decade, anti-
DNA has been reported to crossreact with related poly­
nucleotides10 and with other polynegative structures such 
as phospholipids10"12, proteoglycans1314 and dextran sul­
phate15 Other crossreactive targets include membrane-
associated proteins16, cytoskeleton-associated struc­
tures17, and histones18 or DNA-histone complexes19 In 
terms of pathogenesis, the proteoglycans, amongst 
which is heparan sulphate, the major glycosaminoglycan 
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qf the glomerular basement membrane, and the lupus-
associated membrane protein (LAMP)16, seemed to be 
attractive targets for crossreactive anti-DNA to trigger 
inflammatory responses 
Avidity and crossreactivity 
The validity of this hypothesis has also become a matter 
of debate Lupus nephritis is strongly associated with the 
presence of high-avidity IgG anti-DNA in the circulation of 
patients20 and in eluates from affected kidneys3 A role for 
low-avidity anti-DNA in the induction of nephritis is there­
fore unlikely This calls into question the significance of 
crossreactivity since mainly low avidity anti-DNA anti 
bodies crossreact with cardiolipin and dextran sul­
phate12 7' Furthermore, doubt has been expressed as to 
the extent that the monoclonal anti-DNA used in 
crossreactivity studies truly represents the pathogenic 
anti-DNA populations found in patients' sera22 most of 
the monoclonal antibodies to DNA have been of the IgM 
isotype and/or were only screened for anti-DNA reactivity 
in an anti-DNA ELISA This assay biases the selection of 
anti-DNA towards low-avidity antibodies7' and so there 
is a considerable risk that the selected low-avidity IgM 
antibodies belong to the group of so-called 'natural auto 
antibodies' - antibodies of the IgM isotype, present in 
normal individuals that crossreact with several tissue con­
stituents23 24 In this context it would be interesting to 
determine whether the selected monoclonals react in 
other anti DNA assays, such as the Farr assay, in which 
much higher avidity is necessary to give a positive signal21 
In fact, we would like to propose that the term anti-DNA 
should be applied only if a positive anti-DNA ELISA can be 
confirmed by positive results in at least one other anti-
DNA assay, since we have found that the anti-DNA ELISA 
system is prone to false positive errors (Brinkman et al, 
unpublished) 
Immune complexes and crossreactivity 
Recent observations discredit the model of crossreac­
tive anti-DNA even more completely In culture super-
natants of anti-DNA-producmg hybndomas, both free 
anti-DNA antibodies and immune complexes, formed 
between anti-DNA and DNA and released from (dying) 
cells, are present These immune complexes were found 
to be responsible for many crossreactive binding patterns 
for example, when a monoclonal anti-DNA found to be 
'crossreactive' with histones was appropriately purified or 
treated with DNase, not only were the immune complexes 
remove  but also the binding of the antibody to histones 
ceased, w ile the binding to DNA itself was unaffected or 
even increased182526 When a panel of monoclonal anti-
©1990 Elsevier ScencePubhsneri Lid UK 0167 4919/90/Ш 00 
47 
DNA antibodies was used, removal of the complexes had 
little or no influence on the binding of anti-DNA to 
cardiolipm or dextran sulphate However, the"crossreac-
tive' binding of anti-DNA to histones, heparan sulphate 
(HS) and unidentified immunoblotted cellular structures 
almost completely disappeared after this procedure, while 
the addition of small amounts of DNA could m part restore 
the signals again26 Similar observations were made for 
the anti-DNA binding to LAMP purification of a LAMP-
reactive monoclonal anti-DNA removed the LAMP reac-
tivity Interestingly, LAMP turned out to be a histone-like 
protein27 
Further experiments have revealed that two different 
routes can lead to the binding of anti-DNA to HS First, 
DNA-anti-DNA immune complexes can bind to the pre-
coat used in the anti-HS ELISA, giving rise to a false-
positive 'crossreactive' binding of anti-DNA Second, 
DNA anti-DNA immune complexes may also contain his-
tones and these so-called anti-DNA-nucleosome com-
plexes may bind to HS through their histone component 
(Termaat ef al, unpublished) 
The crossreactive binding of anti-DNA to histones, 
heparan sulphate or LAMP is, therefore, unlikely to play a 
role in the induction of lupus nephritis Nevertheless, 
these structures themselves may be important in the 
pathophysiological process Recently, Schmiedeke ef a/2 8 
found that histones can bind to the glomerular basement 
membrane of healthy rats in vivo, causing deterioration in 
glomerular function28 The suggested target for this bind-
ing, which appeared to be of a very high avidity, was 
heparan sulphate Moreover, bound histones retained the 
capacity to bind specific antibodies and DNA These find-
ings suggest a central role for histones and heparan 
sulphate in the initiation of glomerular immune complex 
formation Although the authors do not mention a role 
for anti-DNA antibodies, they may very well be involved 
once histones and DNA are bound, attachment of cir-
culating anti-DNA antibodies is likely This concept is 
substantiated by our recent findings that anti-DNA anti-
bodies can bind via DNA-histone complexes to isolated 
glomerular basement membranes m a fine granular 
fashion (Termaat ef al, unpublished) 
Summary and conclusions 
Although the role of anti-DNA antibodies in the patho-
genesis of lupus nephritis remains unknown, we believe 
that direct binding of these antibodies to crossreactive 
epitopes plays no major role m the process First, 
crossreactivity is restricted to antibodies with a low avidity 
towards DNA, whereas lupus nephritis is associated with 
high-avidity anti-DNA antibodies Second, the mono 
clonal anti-DNA antibodies used to study the crossreactive 
binding patterns are mostly of the IgM isotype and/or of a 
low avidity and therefore do not represent the anti-DNA 
population associated with disease Finally, many of the 
previously reported crossreactions in vitro were artificial 
and caused by immune complexes formed by anti-DNA 
antibodies and DNA or DNA-histone complexes 
Launched as an alternative explanation to the immune 
complex theory of SLE nephritis, the model of crossreac-
tive anti-DNA has itself been found to be based on 
immune complexes and has turned attention back to the 
original hypothesis However, this hypothetical excursion 
has led to the discovery that the complexes might be more 
complex than was originally thought not only DNA, but 
anti-DNA avidity 
low high 
CROSSREACTIVITY NEPHRITIS 
Fig. 1. Based on experiments with monoclonal anti DNA anwodies, we believe 
thatsera of individual SLE patients œntam a spectrum olanti DNA antibodies with 
varying avidity towards DNA At one end of the spectrum bw avidity anti DNA 
antibodies are apt to crossreact with structures like cardiolipm and dextran-
suiphatefDXSi thepreseiceof these antibodies in sen does not correlate with the 
appea'ance of lupus nephntis At the other endo' the specfum, high avidity anti-
DNA antibodies seem 'o be involved in the pathogenesis of lupus nephrAs, these 
antibodies can form immune complexes with DNA histone oandes and sub-
seaijently adhere to the glomerular basement membrane 'GBMÌ through the 
interaction of histones with heparan sulphate 
also DNA-histones (as had been advocated previously29) 
complex with anti-DNA and bind tissue-related structures. 
New studies, notably on the interaction between heparan 
sulphate and histones29 have opened new pathways for 
the elucidation of the true involvement of anti-DNA in 
lupus nephritis 
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Anti-heparan sulphate reactivity in sera from patients with 
systemic lupus erythematosus with renal or non-renal manifestations 
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SI MMARY 
PrcviousK wc hd\c shown that anli-DNA can bind to heparan sulphate (US) a Lonstiluent oflhc 
glomerular basement membrane (GBM) We hvpothcsired that binding ol anti-DNA to Hb in the 
GBM р1а\ь a role in the onset ol systemic lupus crvthemalosus (SI L) nephritis To test this 
hypothesis we measured the anti-HS reactivitv in cross-sectional and longitudinal studies of SLE 
patients with or without nephritis In the transverse serum study single serum samples from 26 SLE 
patients were studied We lound no correlation between anti HSrcactmiv and previous development 
of nephritis (anti-HS positive seven out of 16 with hislorv ol nephritis two oui ol 10 without 
nephritis) However six of the seven anti-H S positive sera in the nephritis croup were obtained within 
I month of the onset ol nephritis suggesting a temporal rclalionship between anli-HS reaclnilv and 
onset of nephritis In the longitudinal scrum studv between six and 16 scrum samples were studied 
from each oí 10 SI Е-рліепі> In hve out of five episodes ol nephmis we lound anli-HS rLdCtivit> 
bclorc the onset or exacerbation o( the nephritis In lour non renal manifestations anti-HS reactivity 
was found in onlv one episode m none of the three patients who remained climcallv stable did serum 
samples show anti-HS reactivitv Ann US reactivitv was onlv found in sera positive foranti-DNA bv 
Farrassav but the anti-HS titre was not a mere reflection of the reactivitv measured in the Farrassav 
This indicates that onlv a subpopulation of anti-DNA can bind to HS We found a high corrüation 
(r = () 99) between anli-HS reactivities in plasma and scrum and we conclude thai ant ι-HS reactivity 
in serum samples from SI E patients is not due lo in uno complex lormation during clotting 
Although further prospective analysis is netessarv our dala suggest thai measurement ofanli-HS 
reactivitv in SLF patients might idennfv patients at risk for the development ol nephritis 
Kevwords svstemic lupus crvlhematosus nephritis anli-DNA heparan sulphate cross-
rcactivitv 
I N T R O D I C T I O N 
Antibodies drrecled against dsDNA are characteristic for the 
autoimmune disease svstemic lupus crvlhematosus (SLE) (Tan 
1982) An association belwccn increases oí levels of anli-
dsDNA antibodies in the scrum and flares ol disease activity has 
been reported (Swaak et ai 1979) Especiallv high aviditv anti-
dsDNA antibodies are believed to plav a pivotal role in the 
development of SLE nephritis (Koffler Schur & Kunkel 1967 
Lambert & Dixon 1968 Winfleld Faiflermaη & Koffler 1977 
Swaak & Smeenk 1985 Raz et al 1989) SLE is general^ 
regarded as an immune complex-mediated disease in which 
Correspondence Dr R M TermaJt Division of Ncphrologv 
University Hospital PO Box 9101 6МДО UB Nijmegen The Nether 
lands 
deposilions of DNA anti-DNA complexes arc held responsible 
for the development ol the various disease manifestations In 
this concepì deposition of immune complexes m the glomeruli 
leads lo theonscl ofncphniisiKoflieren//. 1971) However the 
presence of DNA anli-DNA complexes in ihe circulation and 
the precise mechanism through which anli-DNA can cause renal 
injur> has been a matter of much debate and conirovcrsv 
(reviewed bv I ournie 1988) 
Recenti ν an alternativ e explanation forthcpathogenicitv of 
anti DNA has been proposed It has been suggested that a direct 
cross-reactive binding ol anti-DNA lo epitopes present within 
the glomerulus or glomerular basement membrane (GBM) 
might cause SLE nephritis (E-ilal 198^ laabertVi// 1985 1986 
Madaioi/tf/ 1987 Ra/t/i// 1989 Sabbaga Í / a/ 1989) We 
have shown prtviouslv (baabcrt/ al 1985 1986) that polvclo-
nal anti-DNA antibodies can bind to heparan sulphate (HS) the 
53 
ghcosaminoglvcan sidcchainol hep irán sulphate proteogKcan 
(HSl'G) vihich is an intrinsic constituent of the GBM Tins 
НЬРСі is the major proieogl>can ol the GBM and is responsible 
lor the negative charge of the GBM and its charge-selective 
pcrmeabihts (barquhar el ul 1982 Kanwar & Jakubowski 
1984 Croggele/n/ 1988) We postulated that binding of anli-
DNA to this HS in the GBM might plav a role in the initiation of 
SI F nephritis Thcrefoic we studied the HS rcaclivil> in scrum 
samples obtained transvcrsclv as well as [ongiludinall> from 
SI E patients with nephritis and or non renal disease mamles-
talions 
Recenti) we found that monoclonal anti-DNA antibodies 
react with HS via antibodv-bound DNA histonc complexes 
(Brinkman el ul 1989 Tcrmaat(/a/ 1990) Because ncclco-
sonics can be released during clotting serum mav also contain 
such complexes To stud) the influence ol complex lormalion on 
the reactivity of polvclonal anil DNA antibodies to US »c 
tested HS reacliviiy in simullaneouslv obtained scrum and 
plasma samples Irom a dilTerent group of SI E patients 
M A T F R I A 1 S AND M E T H O D S 
Puiitnis 
Trwniffw VÍUÍ/I A single scrum sample from each of 26 
patients with an established diagnosis of SI EOullfilhngat least 
four of the revised American Rhcumalolog) Association en-
tena Tan el al, 1982) was analysed blind in the an4-DN<\ 
assays and the anti-HS ELISA For each patient a cumulative 
clinical nephritis score was calculated according to the method 
described bv Sluiter el al (1981) The clinical records of the 
patients were screened for the parameters listed in Table 1 
during the lime between the onset of SI E and the time-point the 
serum analysed was obtained Haemaluna was defined as the 
presence ofal least live dvsmorphtc erv throcyIcs per high-power 
held (HPI ) I'nnarv protein excretion was evaluated on the 
basis ol at least three consecutive measurements in 24-h 
collections and the creatinine clearance was calculated as the 
mean value ofat least three consecutive measurements Since a 
clinical nephritis score of >2 is associated with significant 
abnormahlics m kidney biopsies in SLE nephritis (Sluiter < / al 
1981) patients with a clinical nephritis score > 2 were classified 
as patients with nephritis those with a score g 2 were allocated 
to the group without nephritis 
/ onguudmal srwi/i For this study 10 patients were selected 
by an independent investigator (J N ) on the basis of their 
clinical history Irom a cohort ol 110 SI E patients (all seen bv 
one clinician. A S ) Details about this cohort of patients have 
been published (Swaak el al 1989) Scrum samples were 
obtained at each control visit at the Outpatient Clinic Selection 
criteria for the periods from which serum samples were to be 
analysed were either (i) periods in which patients remained 
clinically stable (it) periods with a non-renal manifestation 
without any signs of nephritis, or (in) periods with a biopsy-
proven diffuse proliferative SLE glomerulonephritis (WHO 
class IV) For the assessment of the various disease manifes-
tations the SLE disease activity index (DAI) definitions were 
used (Chang el al, 1986) The anli-DNA profile was not taken 
into account for this selection Patient characteristics arc listed 
in Table 2 In addition, the maximal SLE disease activity during 
the period Ihe sera were collected as defined by the validated 
SLE DAI scoring system (Chang et al, 1986, Liang et al 1989), 
(able I Clinical ncphnlis score m St F 
(according to Sluilcr if ul I9KI) 
No ol 
Parameter points 
Hucnialuru 1 
Гг іЬгос іе casts 1 
Prolcinuna > I S g 2A h I 
Prolcmurij > 1 S g 2Λ h 2 
Oliguria ( < «О ml 24 h) 2 
( rcatininc clearance ^ 120 ml mm I 
С гсаипте· clearance < 60 ml mm 2 
is given During the study period, patients I 4, and 5 remained 
clmicallv stable patients 2, 3 and 10 experienced a non-renal 
manifestation, while patients 6, 7 8 and 9 developed biopsy 
proven glomerulonephritis Furthermore patient 7 also experi­
enced a non-renal manifestation during the same period and 
patient 9 developed after an initial improvement a severe 
exacerbation leading to end-stage renal failure 2 months after 
the onset of nephritis The serum samples were coded and 
blinded for the chrical dala before being analysed in the I arr 
assay, the anti-DNA ELISA and the anti-HS ELISA 
AnihD\ Ï annbocl} ímí / i s 
Anti-DNA antibody activity was determined in both the anti-
DNA FI ISA and the Farr assay as described previously 
(Aarden & Smeenk. 1981 Faaber el al 1986) 
4nii-FiS H IS4 
MS punhed from bovine kidney was purchased Irom Scikaguku 
KogvofTokvo Japan) and thcanti-IIS El ISA was carried out 
as described previously (Faabcr el al 1986) 
The litre in both FI ISAs was defined as the reciprocal 
dilution of the sample giving an absorption ol I Oat 4^0 nm In 
all ELISAs scrum and plasma samples were also tested on wells 
m which during the coating procedure butter without antigen 
was used A panel of normal serum (н = 50) and plasma samples 
(n — 50) was used as negative control in all assays Based on 
results obtained on these control samples patient samples were 
considered positive if (he litre m the ELISA was > 8 and the 
reactivity in the I arr assay > 20 U ml 
Sttilislnal amih siv 
For statistical analvsis the / test and the Pearson correlation 
lest were used 
R E S I I.TS 
Anti-US aiutiti in serum samples of tin trutmerse 4tu(l\ 
Scrum samples from 26 SLE patients were studied for the 
presence of anti-HS reactivity Results obtained arc summarized 
in Table 1 There was no correlation between anti-HS reactivity 
in the scrum and the clinical nephritis score (/-= 1 54 Ρ-ΰ2\) 
Since the clinical nephritis score was based on the cumulative 
presence of nephritic symptoms during the disease course a 
clinical nephritis score > 2 did not necessarily express a 
clmicallv active nephritis at the moment the analysed serum 
sample was obtained When we analysed the seven sera with a 
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Table 2 Pdticni charjctenstics ofihe longitudinal scrum study 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
Sex 
M 
h 
Γ 
ь 
F 
F 
M 
Year 
of 
birth 
1942 
1948 
1918 
I9V7 
1934 
1967 
1924 
Duration of 
SLF prior to 
serum study 
(months) 
30 
120 
9 
156 
180 
4 
24 
Previous disease 
nunifestalions 
Cerebral SI E 
leucoeylopenia 
thrombocytopenia 
Raynaud s phenomenon 
Cerebral SLE skin rash 
pericarditis 
Icucocytopcma Raynauds 
phenomenon arthralgias 
Cerebral SLE skin rash 
arthritis 
Sicca syndrome skin rash 
skin vasculms arthralgias, 
cerebral SLF 
Skin rash arthralgias 
pleuritis 
Skin rash arthralgias 
anaemia Raynauds 
phenomenon 
Skin rash arthralgias 
leucocytopenia 
thrombocytopenia 
Raynaud s phenomenon 
fever 
Scrum 
samples 
studied 
(n) 
10 
14 
14 
10 
6 
10 
16 
Duration of penod 
studied serum 
samples were 
obtained (months) 
12 
24 
2 
S 
21 
7 
22 
Disease aclmtv 
during scrum 
study 
Clinically stable 
Cerebral SLF 
Thrombocytopenia 
leucoevtopenia 
С linicalls stable 
Clinically stable 
Nephrotic svndrome 
dilluse proliferative GN 
Diffuse proliferative ON 
skin vasculitis 14 months 
after onset of nephritis 
Maxim il 
SLF DAI 
score* 
-» 
16 
8 
1 
2 
24 
18 
1961 
Skin rash vasculitis 
arthralgias Raynaud s 
phenomenon 
Skin rash arthralgias 
Raynaud s phenomenon 
DifTusc crtscentiL GN 
Diffuse рго1іГегаіі\с G \ 
Diffuse cresccntiL GN after 
2 months exacerbation 
leading to FSRD 
Polvarthniis 
• During observation period scrum samples were studied 
SLE. svslemic lupus ervlhcmalosus DAI disease activity index GN glomerulonephritis bSRD end-stage renal disease 
Table λ Transversal study relation between 
anti IIS reactivity in the serum and üinical 
nephritic store in 26 SLI patients 
Clinical nephritis score 
<2 
Anti HS PLISA 
Positive 
Negative 
/ - I 53 P = 02\ 
MS heparan sulphate SIE, systemic 
lupus erythematosus 
positive anti-IIS ELISA in the nephritis-positive group for the 
relation to disease aUmty at the moment the serum was 
obtdincd we found that six out of seven serum samples were 
Lolletlcd within a period of 1 month of the onset or exacerbation 
oí SLE nephritis while this was not the tase for the nine anli-
HS-ncgalive sera in this group This suggested a limited 
temporal relationship between anti-HS reactivity and onset of 
nephritis Wc therelorc decided to carry out a study on 
longitudmallv obtained scrum samples from SI E patients with 
or without renal manifestations 
Anti-HS actnity in serum samples of the longitudinal stud\ 
In the longitudinal study six to 16 scrum samples per patient 
were tested in the Farr assay, the anti-DNA ELISA and ihc anli-
HS FI ISA Representative examples of the antibody profiles 
obtained arc given in Fig I These four patients were seletled 
because their clinical course during the study period represents 
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hiß I I our diiynniii of anlibod\ profiles in four dilKruit patitnls Г)а\ 0 is Un. time point at which the first scrum studied was 
obi imcd ЛпііЫнК acliv)1\ wasnuasurnl in IIS Í I ISA (O)and Ï arrassa\ (л) A titre in Π ISA ol π S and a reicli\u\ in the I arrof 
i IO I nil shonid he regardai as ncg i m e R onset οί ι renal mamleslation \ non renal manilcsiaiion (a) pit icntJ (b) patient 2 
(e) patient 7 (d) patient l) 
Table 4 Relation between heparan sulphate (HS)rc*aclivil\ 
and disease manifestation in longitudinal studv 
ex; 
-cc 
Days 
Fig- 2. (a) Relation between titre in the Farr assay for the four patients 
with a primary renal disease manilestalion and onset of nephritis at day 
0 (b) Relation between litre anti HS FLISA and onset ol nephritis al 
dayO О patient 6 О patient 7, Δ patient 8 U patient 9 For patient 9 
the exacerbation ol nephritis is depicted by an arrow 
Number 
ol episodes 
Manilcsiaiion or patients HS positive 
Onset esaeerbalion of nephritis S S 
Vtn rcinl mamlestation 4 I 
( ImiLulK stable (patients) 1 0 
rcspcctivel} a stable course ([ ig la) a non renal exacerbat ion 
( h g lb) a renal and a non-renal m a m f c s u i i o n ( H g k ) . m d a n 
onsei ol renal mani lcs ia i ion with a subsequent exacerbat ion ol 
t h e n e p h n l i s d it: Id) In all these p a t i e n l s a n l i - D N A anliboelies 
were found in the circulat ion as measured in the a n h - D N A 
F l ISA a n d or ihc F a r r assav 
In I tg 2a the results in the F a r r assav arc depicted for the 
four pat ients (pat ients 6 7 8 and 9) who developed nephri t i s 
da\ 0 represents the onset ol nephrit is In all cases high reaclivtlv 
in the F a r r assav preceded the dcvelopmenl of SI E nephrit is 
I hese findings arc in a c c o r d a n t e with those prewouslv p u b ­
lished (Swaak it al, 1979) In Fig 2b the ant i-HS r c a t l m u is 
given m a similar wa> lo i l lustrate the relationship between onsei 
ol SI fc n c p h m i s and IIS rcacti\il> In all cases anli H S 
rci i t t iv iu is deiecldblc pr ior to the onset or c t a c c r b a t i o n ol the 
nephrit is F u r t h e r m o r e it is noteworthy that after the develop­
ment of the nephrit is the ami H S ñ ires raptdK decreased A 
summar> oí the results for all sera tested is given m Table 4 In 
the five episodes ol an onset ol exacerbat ion of SLE-nephn t i s wc 
found in all cases an t i -HS r e a t l m i y in ihc serum samples before 
ihc onscl In the lour episodes of an onset o r exacerbat ion oi a 
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Farr assay (J/ml) 
hß . 3 RL] ilion benvet-n гслсіі\іііі.ч in ιΐκ Ι лгт is^w and tilt ami US 
I I IS \ ol sera sludiul in thi. hmgiiudina] siud\ (/ 0 14) 
non-renal disease m.milesialtons we Γη und anli-HS rea(.U\il\ 
onl> in one palient In this paiienl (paiieni ^) anli-HS геаеіі\іі> 
was lound LonLomilanth with ihe dL\elopnienl ol a IcucotWo-
penia and ihrombiK\topcnia С linitalK no siyns ol renal 
unoKcmerii were present 1 mallv three palienis remained 
elinicalK stable during the whole period serum samples were 
oblaincd and in none of these patients anli-HS reaeli\il\ was 
deletlablL whileanti-DNA antibodies wei e piesuH in twool the 
three patients (barr assa\ 200 4)0 1 ml) These dala suggest 
an assoeulion between an onset exacerbation ol SI F nephiitis 
and ant ι US reaetmlv in the serum Although I ig 2 could 
suggest that high barr reactivities aie aeeompamed b\ high anli-
HS litres the individual profiles piesenied in I ig 1 indicate ι ha I 
this is not alwavs ihe ease II anli-HS levels jre plolled agamsl 
ihcKirrassav reaeii\ilies(l· ig 1)it beeomcscleai ihatiheanti-
HS level is not a mere refleelion ofihe harr reaedviiv although 
we nc\erobsei\ed anli-HSreaclivitv in ϊ arrass.iv negative sera 
These data indicale that onlv in certain situations anli-D\A 
antibodies aie lormed which bind to HS As oullined earhei a 
high harr and anli-HS reaclivitv seem lo bc associated vuih 
development ol SI ϊ nephnlis whereas high reaetiviiv in the 
I air assav wiihoul anli-HS reaclivitv seems io occur in non­
renal SLF disease manilcstalions No correlation was lound 
between ihe maxima) SI l· DAI observed within periods ol λ 
months and the maximal anli-HS litre С —0 ^4) or the maximal 
anii-DNA litre (/ —О ^H) in the same period 
inti-HS it'dLiuit) in plasma (ompaud with \inmltancous/\ 
ohtaint'ii si mm 
One should be cautious when studvingcross-reaclivitv patterns 
ol ami ONA antibodies since complexes containing DNA and 
histones can disturb the reaetiviiv patterns ol anti-DNA 
antibodies as we (ound with monoclonal anli-DNA antibodies 
(Brinkman it а/ 1УН9 Tcrmaat < t at. 1990) Such complexes 
can he present in sera since К is known lhal DNA and other 
nuclear antigens are released during cloning (Stemman 197^) 
However, plasma samples ol these patient* were not available 
Therefore we studied simultaneousK obtained scrum and 
plasma samples Irom another group ol SLL patients The anti-
US reaetiviiv in scrum and plasma ol seven diHcrent SI Г 
patients was compared We found a high correlation between 
the reactivities in scrum and plasma U = 0 99) From these 
results we conclude lhat the anti-HS reactivities measured in 
scrum samples I ю т Ы F patients is noi due lo m t ino complex 
lormalion between anti-DNA and DNA and histones 
DISCISSION 
In a previous sludv we lound [hat certain S I I sera contain 
antibodv reaclivitv against HSil aaberm// I9S6) Thebindmn 
to HS could be inhibited in a dosc-dependenl manner b\ DN \ 
whereas HS could inhibit the binding to DNA I hat anli-DN A 
antibodies were indeed responsible lor this anli-HS reaclivitv 
was lurthcr subslantialed bv ihe Imding that two monoclonal 
anii-DN \ antibodies also bound ю MS Oui Imding lhat 
antibodies eluted Irom human and murine kidnevs with prolifer­
ativ с SI L nephritis also showed a DN Vinhibitable binding lo 
IIS suggested lhat this anti-HS reaclivitv could have a patho 
genetic significance Ha sed on ihesc icsuliswe hvpothesi/ed that 
direct binding ol ami DNA to IIS an intrinsic consti I uenl ol ihe 
GBM could be important in the initiation ai SI I nephritis 
Io lesi the clinical significance ol anli-HS reaetiviiv lor ihe 
developmenl ol SI I nephritis wc analvsed the presence of anli-
HS rcactivit> m the serum of patients in relation to the 
development ol glomerulonephniis I usi we investigated 
whether we could idenlilv aim MS binding m a single sei um 
sample Irom patients who had developed glomerulonephniis
 tit 
an\ time prior to ihe moment the anal>sed serum sample was 
drawn In this transveise cohort sludv we did not lind a 
signihcanl dillerence between patients who had developed a 
glomeiulonephnlis previouslv and those who did not Mote 
detailed analvsis oflhc nephritis positive group showed lhal six 
ou Lol seven anti MS-posiiive sera were obtained within 1 month 
ol the onset ol gIomc,rulon<_phntis uhilc the nine negative 
serum samples were oblaincd aller a much longer interval aller 
the onset ol nephnlis I hese resulls indicale lhat SI [ patients 
with a histoiv ol glomerulonephritis can not be idcnlihcd bv the 
continuous presence ol antibodv icaelivitv against IIS Furlhci-
niore thev suggest that aim HSieactmiv ispicscnt lora limned 
time around ihe onset ol the glomerulonephniis Fherclore we 
expanded our stud ν bv a nal ν sing agi cal number ol sei a Irom 10 
SLL patients selected for then ehmeal disease aelivilv 
In this longitudinal sei urn studv we were able to demon-
sliatc thai all patients with a kidncv biopsv-proven dilluse 
proli (era live SI L glomerulonephniis (WHO class l\ ) had anti-
HS reaclivitv in their sei urn pnoi to the onset ol the nephnlis 
while this was lound in onlv one out ol lour episodes ol a non 
renal disease manilestation In patients with clmicallv inactive 
disease no anti-HS reaclivitv was lound eilhci Remarkablv in 
palienlswiih nephritis anli-HS litres decreased rapidlv alter the 
onset of ihe nephritis 1 his mav be due either to the mlensilicd 
immunosuppressive therapv alter the diagnosis ol nephnlis or 
io a prelerential binding ol HS-ieactive antibodies to ihe 
kidnev Ihe faci that anli-HS litres lell more rapidlv than the 
I arr reactivities (Fig 2) is in favour ol the latter possibihlv 
Our initial idea was lhal anli DNA antibodies bound 
diiecllv to HS viaeross-rcaetiverceoimitiond aabert r al 198^ 
1986) However based on our studies ol monoclonal anti DNA 
antibodies we had lo icadjusi this hvpothesis because this 
binding occurred through nuclear conslituenis complexed to 
anli-DNA antibodies (Termaal et al 1990) Alter alhnilv 
purification of monoclonal anti-DNA antibodies under disso­
ciating conditions on protein A Sepharosc 4H the binding to 
HS was completelv abolished while addition ol 4H column 
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l-ig 4 Dugnim dtpiciing the hinding ol anli DNA «inlibodics to 
heparan sulphalc (HS) in the glomerular basement membram. (GBM) 
The binding is mediated \ia hisione DNA complexes 
cHluent o r D N A together with histones Lomplctel> reconsti-
Uiled this b inding This reconst i tut ion was not observed alter 
addi t ion o f h i s t o n c s o r D N A alone The nuclear material b o u n d 
to 'eross-reacting ' a n l i - D N A m o n o c l o n a l ant ibodies was subse 
quentl> identified t o conta in both D N A and histones F r o m 
these exper iments we concluded that the histone p a n of the 
complex mediated the b inding to H S ( H g 4) These findings are 
further subs tant ia ted by those recenti) reported b> Schmicdckc 
aal ( 1 9 R 9 ) u r h o f o u n d i h a t histones displayed a highavidtt> for 
both hepar in (a H S a n a l o g e n ) m atro and the G B M m ino 
Recently wc found that histone D N A complexes can mediate a 
fine g r a n u l a r b inding of a n t i - D N A to the G B M both m litro 
(isolated G B M loops) a n d ш mo (renal perfusion studies) 
( T e r m a a l í V t í / , manuscr ip t in p repara t ion) Based on these data 
one can a rgue thai the observed H S binding of the sera described 
in this study is the result of nucleosome a n l i - D N A complexes 
that a rc formed du r ing clot t ing after venepuncture Al though 
we can not formally exclude this possibility, the results obta ined 
on simultaneously collected paired serum and p lasma samples 
from an addi t iona l g r o u p of SLE pat ients makes this possibility 
very unlikely as the H S binding in these blood samples was 
identical This would imply that the an t i -HS ELISA identifies 
both m scrum and p lasma a n t i - D N A ant ibodies complcxed to 
nucleosomal mater ial The validity ol this concept is further 
subs tant ia ted by our preliminary findings that purification 
under dissociat ing condi t ions of paired scrum and plasma 
samples from the same individual d e u c a s e d the an t i -US 
reactivity to the same extent in plasma (70" ) as in serum (72" •), 
whereas the a n t i - D N A reaclivily remained unaltered 
Recently R a / et al (1989) reported that a n l i - D N A IgG 
obta ined from pat ients with lupus nephrit is bound in the 
isolated perfused rat kidney to glomeruli and induced a lbumi-
nuria , m cont ras t to IgG isolated from SLL pat ients without 
nephri t is T h e IgG was purified from these h u m a n SI fc sera 
under non-dissociat ing condi t ions on a DL-52 co lumn The 
invest igators concluded from these observa t ions that the iso-
lated a n n - D N A bound directly to intrinsic g lomerular ant igens 
However because of their isolation procedure к is conceivable 
that they have isolated a n t i - D N A ant ibodies complexed to 
D N A histones and that binding to g lomerular H S is mediated 
via the histon part of the complex b o u n d to the ant ibody 
T a k e n together with the above report , o u r study indicates 
tha i m e a s u r e m e n t of a n t i - H S reactivity in serum or p lasma of 
S L L pat ients might idcntilv pat ients at risk for the development 
of lupus nephrit is 
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CHAPTER 6 
Anti-DNA antibodies can bind to the glomerulus via two distinct 
mechanisms 
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ABSTRACT 
Antibodies to doublestranded DNA (anti-DNA) are regarded as a 
diagnostic marker for the autoimmune disease Systemic Lupus 
Erythematosus (SLE) and it is generally assumed that these 
antibodies play a pivotal role in the pathogenesis of SLE 
nephritis. Recently, we reported that anti-DNA antibodies can 
bind to heparan sulphate proteoglycan (HSPG), a constituent of 
the glomerular basement membrane (GBM), via histones and DNA. We 
postulated that these histone/DNA/anti-DNA complexes can bind via 
their histone part to the glomerulus in vivo. To test this 
hypothesis we performed in vitro binding studies with isolated 
GBM-loops and renal perfusion studies in the rat using histones, 
DNA and two anti-DNA monoclonal antibodies (mAb) with different 
avidities for doublestranded DNA (dsDNA) . In vitro we did not 
observe direct binding of anti-DNA Mab to isolated GBM-loops but, 
after preincubation with histones and DNA, a strong granular 
binding to the GBM was observed of both anti-DNA mAb. 
Furthermore, after preincubation with DNA alone, a moderate 
granular binding to the GBM-loops was also found with the high 
avid anti-DNA mAb. In an ex vivo perfusion model, in which 
successively histones, DNA and either anti-DNA mAb were perfused 
directly into the left kidney, a strong binding to the glomerular 
endothelial cells and to a lesser extent in the lamina rara 
interna of the GBM was found by immuno-electron microscopy (IEM). 
Perfusion of DNA alone resulted in binding to mesangial areas 
only when the high avid anti-DNA mAb was subsequently perfused. 
When the high avid anti-DNA mAb was injected intravenously 1 hour 
after perfusion of histones and DNA into the left kidney (in vivo 
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perfusion model) a strong binding in a membranous pattern along 
the capillary wall and a lesser binding to the mesangium was 
observed by direct immunofluorescence (IF). In the IEM small 
subepithelial immune deposits could be seen, a localization quite 
different from the one observed in the ex vivo procedure. When 
the high avid anti-DNA mAb was given intravenously after renal 
perfusion of DNA alone, small deposits in the mesangial areas 
were observed. No binding to the glomerulus was observed after 
injection of anti-DNA mAb alone or when an irrelevant mAb was 
used instead of anti-DNA in the two perfusion models. Glomerular 
binding of anti-DNA mAb either via DNA alone or via DNA/histone 
complexes induced an enhanced albumin excretion. It is concluded 
that anti-DNA mAb can bind to the glomerulus via two distinct 
mechanisms: 1) binding to mesangial areas via DNA alone; 2) 
binding to the capillary wall via histones and DNA. Binding via 
both mechanisms may be involved in the development of SLE 
nephritis. 
INTRODUCTION 
One of the most severe disease manifestations in patients with 
SLE is the development of renal disease and it is assumed that 
especially complement-fixing antibodies of the IgG class which 
bind to dsDNA with high avidity are involved in the pathogenesis 
of SLE nephritis '. Periods of active renal disease are 
associated with elevated levels of anti-DNA and depression of 
serum complement levels 2·3. In addition, the presence of anti-DNA 
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antibodies has been shown in renal or glomerular eluates obtained 
from SLE patients or mice with SLE-like syndromes 4"10. However, 
the mechanisms responsible for the binding of anti-DNA to the 
glomerulus are still unclear or controversial. Several mechanisms 
leading to the deposition of anti-DNA antibodies in the 
glomerulus have been proposed. The most generally accepted 
hypothesis is the passive trapping of DNA-anti-DNA complexes in 
the glomerular filter "•l2. This assumption was challenged by 
studies claiming that anti-DNA antibodies can bind directly to 
glomerular antigens due to cross-reactions 13'". However, it 
turned out that these presumed cross-reactions of anti-DNA 
antibodies with for instance cell-surface proteins or heparan 
sulphate proteoglycan (HSPG), a constituent of the GBM, were 
mediated via histone/DNA complexes 19'20. Sustained by the findings 
of Schmiedeke et al 2l, who showed that histones can bind with 
high affinity to the GBM in vivo, we recently postulated that 
histone/DNA/anti-DNA complexes can bind via their histone part 
to the glomerulus 22. To test this hypothesis we performed in 
vitro binding studies with isolated GBM-loops and renal perfusion 
studies in the rat using histones, DNA and two anti-DNA mAb, that 
appeared to have different avidities for dsDNA. In this report 
we describe two distinct mechanisms of binding of anti-DNA 
antibodies to different glomerular structures. 1. High avid anti-
DNA antibodies can bind to the mesangium via DNA alone. 2. Anti-
DNA antibodies with higher and lower avidity can bind to 
components of the capillary wall. 
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MATERIALS AND METHODS 
Production and purification of mAb to dsDNA 
Anti-DNA mAb were produced as described previously 23. For this 
study two anti-DNA clones were selected, one with intermediate 
avidity for dsDNA, positive in the Crithidia luciliae assay 
(clone 36) , and the other positive in both the Crithidia luciliae 
assay and the Farr assay (clone 42) and therefore with high 
avidity for dsDNA Ώ. Both clones originate from (NZBxW)Fl mice 
and belong to the IgG2a subclass as determined in an Ouchterlony 
using subclass specific antibodies (Nordic, Tilburg, The 
Netherlands). The concentration of IgG in the different mAb 
preparations was determined by radial immunodiffusion 24. MAb were 
purified with protein-Α sepharose chromatography under 
dissociative conditions to remove potentially antibody-bound 
nuclear antigens such as DNA and histones as described previously 
20,25 
Isolation of glomerular basement membranes 
Glomeruli were isolated from 60 rat kidneys by differential 
sieving as described by Spiro 26. GBM was prepared according to 
the method of Meezan et al 27 with slight modifications. Briefly, 
glomerular cells were lysed overnight at 40C in distilled water 
containing 0,1% sodium azide. Then, the lysed glomeruli were spun 
down at lOOOg and washed 3 times with distilled water. The pellet 
was suspended in 40 ml of 1 M NaCl, stirred for two hours at room 
temperature, and spun down at 1000g, subseguently, the pellet was 
resuspended in 4% sodium deoxycholate containing 0,1% sodium 
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azide and stirred for 2 hours at room temperature. Then the 
homogenate was spun down again, the supernatant discarded and the 
pellet washed 3 times in distilled water. Finally the obtained 
GBM material was treated with DNase I (Boehringer, Mannheim) 
under high salt conditions (0,1 M acetate pH 5.0 containing 5 mM 
Mg++, 3 M NaCl and 320 U/ml DNase I) to remove DNA and other 
nuclear material potentially bound to the GBM. Thereafter, the 
GBM material was washed with distilled water and immediately used 
for in vitro studies or lyophilized and stored at -200C. The 
presence of different GBM components was studied with an indirect 
immunofluorescence (IF) using several antisera against GBM 
components; rabbit anti-mouse laminin (Gibco, New York), rabbit 
anti-mouse collagen IV (Collaborative Research, Bedford, Ma) and 
goat anti-mouse fibronectin (Calbiochem, La Jolla, Ca) . Antiserum 
(rabbit) directed against the core protein of HSPG was generously 
provided by Dr L.P.W.J. van den Heuvel (Dept. of Biochemistry, 
University of Nijmegen) 28 and a monoclonal antibody (JM-403) 
directed against the heparan sulphate (HS) side chain of HSPG Ά 
was a kind gift of Dr. J. van den Born (Div. of Nephrology, 
University Hospital Nijmegen). We obtained a strong staining in 
the indirect IF with antisera to laminin, collagen IV and 
fibronectin, a moderate staining with the antiserum to the core 
protein of HSPG but no staining with a mAb directed against the 
HS side chain of HSPG. The isolated GBM neither showed 
fluorescence applying ethidium bromide nor with an indirect IF 
with the high avid anti-DNA mAb (clone 42), suggesting that the 
isolated GBM-loops were free of DNA. Evaluation with electron 
microscopy (EM) revealed that the obtained fraction consisted of 
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GBM-loops with additional mesangial matrix and was free of 
cellular components. Anionic sites were still present as 
confirmed in the EM by the binding of cationic ferritin (Miles, 
Elkhart, USA). 
Binding of anti-DNA mAb to isolated GBM-loops in vitro 
GBM-loops, suspended in distilled water, embedded in Tissue Тек 
(Miles, Elkhart, U.S.A.) and snap frozen in liquid nitrogen were 
cut in 2 /ш thick cryostat sections. GBM sections were 
successively incubated for 30 min at room temperature with 1 
дд/ml histones, 1 мд/ті DNA and purified mAb (15 мд/ті clone 3 6 
or 2 мд/ті clone 42). Calf thymus histones containing all histone 
subfractions were purchased from Boehringer, Mannheim. Calf 
thymus DNA was purchased from Pharmacia, Sweden (sonicated calf 
thymus DNA, phenol extracted, A260/280 1.84, average size 1500 
bases, range 300 - 5000 bases). All solutions were prepared in 
PBS containing 1% BSA. After each incubation step the GBM 
sections were washed for 5 min in PBS. Finally, sections were 
incubated for 30 min with a FITC labeled sheep anti-mouse IgG, 
F(ab)2 antibodies (Cappel-Organon Technika NV, Turnhout, 
Belgium). In control experiments GBM-loops were incubated with 
DNA and mAb, histones and mAb or with mAb alone. The same 
experiments were carried out with an irrelevant control mAb of 
the same subclass (clone WT 32). 
Ex vivo and in vivo renal perfusion studies 
To study binding of anti-DNA mAb to the glomerulus we performed 
renal perfusion studies using two different methods. Male Wistar 
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rats (150g) were anaesthetized by intraperitoneal administration 
of 0.3 ml (18 mg) sodium pentobarbital (Narcovet, Apharmo, 
Arnhem, The Netherlands). After opening the peritoneal cavity, 
an 18 gauge indwelling catheter was inserted into the aorta above 
the bifurcation and positioned directly under the origin of the 
left renal artery. After removal of the inner needle the cannula 
was connected to an infusion system (containing 1% BSA in 0.9% 
NaCl) placed 1.2 m above working level. Immediately thereafter 
the aorta was ligated above the left and below the right renal 
artery and an incision was made in the vena cava to allow the 
escape of blood and perfusion fluid. After the left kidney had 
blanched completely, successively 250 дд histones, 250 jug DNA and 
300 дд Ig of clone 36 or 20 ßg Ig of clone 42 were infused into 
the left kidney in an ex vivo perfusion model and each reagent 
was allowed to bind for 2 min. After each perfusion step the 
kidney was flushed for 30 sec and after the last perfusion step 
for 5 min with saline containing 1% BSA. Subsequently, a small 
part of the kidney was removed and prepared for IF, the remaining 
part was perfused with a mixture of periodate, lysine, and 2% 
paraformaldehyde (PLP) for 10 min and prepared for IEM (see 
below). For the in vivo renal perfusion studies, the second 
method of perfusion, a 24 gauge indwelling catheter was inserted 
as described above however, without incising the vena cava. The 
left kidney was first perfused with 0.3 ml of PBS containing 1% 
BSA (PBS-1%BSA) to remove blood, followed by 0.3 ml of a solution 
containing 250 /ig of histones in PBS-1%BSA, flushed with 0.3 ml 
PBS-1%BSA, and subsequently perfused with 250 дд of DNA dissolved 
in 0.3 ml PBS-1%BSA after which the left kidney was again flushed 
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with 0.3 ml PBS-1%BSA. All solutions were given with the use of 
an 1 ml syringe at a flow rate of 1 ml/min and both histones and 
DNA were allowed to bind for 2 min. Immediately after the 
perfusion the ligature was removed to reestablish normal blood 
flow and the incision in the abdominal wall was sutured. Then, 
after 1 hour anti-DNA mAb (150 μg of clone 42 dissolved in 1 ml 
PBS-1%BSA) was injected intravenously into the tail vein and 
after 30 min the kidneys were prepared for IF and IEM studies. 
Urine was collected by bladder punction and the albumin 
concentration was measured by radial immunodiffusion ™. In 
control experiments perfusion with histones and DNA was followed 
by injection with an irrelevant control mAb of the same subclass 
(clone WT 32) or anti-DNA mAb was injected without previous 
perfusion with histones and/or DNA. 
Immuno-histology. 
After the perfusion experiments 2 μιη cryostat sections from the 
removed kidney tissue were incubated with a F(ab)2 FITC-labeled 
sheep anti-mouse IgG (Cappe1-Organon Technika NV, Turnhout, 
Belgium) for 30 min. After rinsing in PBS, sections were embedded 
in Aquamount (BDH Ltd., Poole, England) and examined with a Leitz 
fluorescence microscope equipped with a Ploemopak epiillumination 
and scored semiquantitatively on a scale from 0 - 4+. The left 
kidneys were prepared for IEM by perfusion with PLP for 10 min, 
were removed and small pieces of renal cortex were immersed in 
PLP for an additional 3 hours. The ultrastructural localization 
in the glomerulus of the anti-DNA mAb was visualized by an 
immunoperoxidase labeling procedure on 20 μιη frozen sections. The 
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small fragments of renal cortex fixed with PLP were rinsed 
several times in PBS, cryoprotected by immersion in 2.3 M sucrose 
buffered with 0.1 M phosphate buffer, pH 7.2, for 1 hour, and 
then frozen in liquid nitrogen. After 3 washes with PBS, the 
sections were incubated with a peroxidase labeled rabbit anti-
mouse IgG (Dakopatt, Copenhagen, Denmark). The sections were then 
preincubated with diaminobenzidine (DAB) medium containing 0.6% 
Tris for 10-15 min, followed by DAB with addition of H202 to a 
final concentration of 0.001% for 7 min. The sections were washed 
in distilled water, postfixed in 0.1 M phosphate-buffered 2% Os04 
for 30 min at room temperature, dehydrated, and embedded in Epon 
812. Thin sections were prepared on a LKB ultratome, and examined 
unstained in an electron microscope (Philips 300, Eindhoven, The 
Netherlands). 
RESULTS 
Binding of anti-DNA mAb to isolated GBM-loops 
The in vitro binding of anti-DNA (clone 36 and clone 42) to 
isolated GBM was studied with indirect IF. The results are 
summarized in Table 1. Neither anti-DNA clone 36 nor clone 42 
bind directly to the GBM (Fig.lA). After preincubation with DNA 
a moderate granular binding was observed with clone 42, but not 
with clone 36. However, after preincubation with histones and 
subsequently with DNA, a strong granular binding was observed 
with both clone 36 and clone 42 (Pig.IB). After preincubation of 
histones alone no binding was observed with either mAb. If an 
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Figure 1 : Indirect immunofluorescence on cryostat sections of isolated GBM-
loops. No binding was found after incubation with either mAb alone (A). After 
preincubation with histones and subsequently DNA, a strong granular binding 
was observed with both anti-DNA mAb, clone 36 and clone 42 (B). 
(A) SOOx; (B) lOOOx. 
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irrelevant mAb with the same subclass and immunoglobulin 
concentration was used (clone WT 32), no binding could be seen 
neither after preincubation with histones, nor after DNA, or 
histones and DNA, excluding non-specific binding to the GBM. So, 
a moderate binding to isolated GBM via DNA is observed only with 
the high avid anti-DNA mAb (clone 42) and a strong binding to the 
GBM via histones and DNA with anti-DNA mAb of relative high as 
well as intermediate avidity for dsDNA (clone 36 and 42). 
Table 1 
Indirect immunofluorescence on cryostat sections of GBM-loops: 
in vitro binding of two anti-DNA mAb (clone #36 and #42) after 
preincubation with histones and/or DNA. Clone WT32 served as 
a control mAb. 
Incubation steps GBM staining 
Anti-DNA mAb #36 
Histones + #36 
DNA + #3 6 
Histones + DNA + #36 3+ 
Anti-DNA mAb #42 
Histones + #42 
DNA + #42 2 + 
Histones + DNA + #42 4+ 
Control mAb WT32 
Histones + WT32 
DNA + WT32 
Histones + DNA + WT32 
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Binding of anti-DNA шАЬ to the glomerulus in renal perfusion 
studies. 
The binding of anti-DNA mAb to the glomerulus was studied in an 
ex vivo and in an in vivo renal perfusion model. The results of 
the ex vivo perfusion studies are summarized in Table 2. After 
perfusing successively histones, DNA and the anti-DNA mAb (clone 
36 or 42) directly into the left kidney (ex vivo model), we found 
a strong staining of the glomeruli, arteries and peritubular 
capillaries by IF (Fig. 2A and C) . By I EM massive aggregates 
could be observed on the cell membranes and in the fenestrae of 
the glomerular endothelia and on the endothelial cell membranes 
of the renal arteries and peritubular capillaries. Smaller 
complexes were also seen in the lamina rara interna, but not on 
the outer side of the GBM (Fig. 2B and D). When DNA was perfused 
into the kidney followed by clone 36 or 42, we only observed 
binding in the glomerulus of the high avid anti-DNA mAb, clone 
42 (Fig. ЗА). In the IEM this binding was exclusively located in 
mesangial areas, mostly between endothelial and mesangial cells; 
no binding was observed on the endothelial cells or in the GBM 
(Fig. 3B). 
A different binding pattern to the glomerulus was observed when 
anti-DNA mAb (clone 42) was administered into the tail vein 1 
hour after the perfusion of histones and DNA into the left kidney 
(in vivo model). This time interval allows the nuclear components 
to penetrate more into the glomerular capillary wall before they 
can serve as planted antigens for the subsequently administered 
anti-DNA mAb. In the direct IF fine granules were seen along the 
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Figure 2: Direct immunofluorescence (A,C,E) and immuno-electron microscopy 
(B,D,F) of the glomerular binding of anti-DNA mAb in renal perfusion studies 
in the rat. After successive perfusion of histones, DNA and anti-DNA mAb 
(clone 36 or 42) into the left kidney (ex vivo perfusion procedure) a strong 
staining of glomeruli (A), peritubular capillaries and arteries (C) is found 
by immunofluorescence. Large aggregates are located on the cell membranes and 
in the fenestrae of endothelial cells of the glomerulus (B) and peritubular 
capillaries and arteries (D) . Smaller deposits are also present in the lamina 
rara interna of the GEM (B). When the anti-DNA mAb (clone 42) is injected 
intravenously 1 hour after renal perfusion of histones and DNA (in vivo 
perfusion procedure), a membranous binding pattern is observed in immuno­
fluorescence (Ε), with immune deposits aggregated in the slit pores and under 
the visceral epithelial cells as seen in the immunmo-electron microscopy (F). 
(A) SOOx; (B) 14500X,· (C) 400x,· (D) 3500x; (E) 500x; (F) 28500x. 
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Figure 3: Direct immunofluorescence (А,С), and immuno-electron microscopy 
(B,D) of the glomerular binding of anti-DNA mAb in renal perfusion studies in 
the rat. After perfusion of DNA followed by perfusion with anti-DNA mAb (ex 
vivo perfusion procedure), binding in the glomerulus was obseved with the high 
avid anti-DNA mAb (clone 42) by immunofluorescence (A). By immuno-electron 
microscopy this binding is exclusively found in mesangial areas (B) . In 
control experiments (see text), both in the ex vivo and in vivo renal 
perfusion studies, no binding to the glomerulus or to blood vessels was 
observed with immunofluorescence (C) or immuno-electron microscopy (D). 
(A) SOOx; (В) бОООх; (С) 400x; (D) 3400x. 
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capillary wall in a membranous pattern while variable amount of 
deposits were also present in the mesangium. The immune deposits 
in the glomerular capillary wall could be located in the slit 
pores and under the foot processes of the visceral epithelial 
cells in the direct IEM (Fig. 2E and F) . Unlike the ex vivo 
perfusion procedure, no binding to the endothelia of arteries and 
peritubular capillaries could now be demonstrated by direct IF 
and IEM. When anti-DNA clone 42 was injected 1 hour after 
perfusion of DNA alone into the left kidney, we found 
considerably less immune deposits in the mesangial area than in 
the ex vivo perfusion model. 
Table 2 
Direct immunofluorescence of the ex vivo perfusion studies: 
glomerular binding of two anti-DNA mAb (clone #36 and #42) 
after successive perfusion of histones, DNA and mAb directly 
into the left kidney. Clone WT32 is a control mAb. 
perfusion glomerulus PTC* arteries 
Anti-DNA mAb #36 
Histones + #3 6 
DNA + #3 6 
Histones + DNA + #36 3+ 2+ 3+ 
Anti-DNA mAb #42 -
Histones + #42 -
DNA + #42 1/2+ 
H i s t o n e s + DNA + #42 4+ 3+ 4+ 
C o n t r o l mAb WT32 -
H i s t o n e s + WT32 -
DNA + WT32 -
H i s t o n e s + DNA + WT32 -
•peritubular c a p i l l a r i e s 
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In control experiments in which histones were perfused followed 
by anti-DNA mAb omitting perfusion of DNA, or in which rats were 
injected with mAb alone, both in the ex vivo and in vivo renal 
perfusion studies, we found no binding in the glomerulus or to 
blood vessels. In addition, no binding of an irrelevant mAb could 
be observed to the glomerulus after perfusion with histones and 
DNA (Fig. 3C and D). 
Induction of albuminuria by glomerular binding of anti-DNA mAb. 
When anti-DNA clone 42 was injected intravenously 1 hour after 
perfusion of histones and DNA into the left kidney (in vivo 
perfusion model) we found a significant increase in albumin 
excretion, measured in two individual rats (Table 3). Also after 
in vivo perfusion with DNA alone and subsequent injection of 
clone 42, an enhanced albumin excretion was observed. The values 
of albumin excretion in the control rats (injection of clone 42 
alone or an irrelevant mAb after perfusion of histones and DNA) 
were in the normal range of physiological urinary albumin 
concentration. We defined the upper limit of the physiological 
urinary albumin concentration as 53 ßg/ral (mean + 3 SD) derived 
from the values of a control group of normal male Wistar rats 
(n=24) being 26 ± 9 ßg/ml (mean + SD) 
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Table 3 
Albumin concentration in urine of single rats injected intra-
venously with anti-DNA mAb #42 with high avidity for dsDNA 1 
hour after perfusion of histones and/or DNA into the left 
kidney (in vivo perfusion model). WT32 is an irrelevant mAb 
that served as a control mAb. The upper limit of the physiolo-
gical urinary albumin concentration is 53 pq/ml. 
Perfusion 
(kidney) 
Histones + DNA 
DNA 
Histones + DNA 
PBS 
Injection 
(tail vein) 
#42 
#42 
#42 
WT32 
_ 
Albuminuria 
(Mg/ml) 
460 
800 
250 
7 
20 
14 
DISCUSSION 
Although it is believed that anti-DNA antibodies are involved in 
the induction of SLE nephritis l, it has been difficult to induce 
glomerular binding of anti-DNA. In some cases, it was only 
possible to produce mesangial Ig deposits 1517. In this report we 
have studied the binding mechanisms of anti-DNA antibodies to the 
glomerulus by performing in vitro binding studies with isolated 
GBM-loops and renal perfusion studies in the rat. We found two 
mechanisms that might explain the binding of circulating anti-
DNA antibodies to two different glomerular components, the 
glomerular capillary wall and the roesangium, areas in which 
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immune deposits are found in SLE nephritis. These two mechanisms 
were discovered by selecting two anti-DNA mAb with different 
avidities for dsDNA, clone 42 with high avidity and clone 36 with 
lower avidity for dsDNA. Both high and low avid anti-DNA mAb can 
localize in the glomerular capillary wall after binding of 
histones and subsequently DNA has occurred. In addition, high 
avid anti-DNA mAb can bind to mesangial areas through DNA alone. 
Glomerular localization of DNA has been described previously :,0·31, 
however in these studies the precise localization within the 
glomerulus at the ultrastructural level was not analyzed. 
Probably, like in our studies, this binding was restricted to 
mesangial areas. 
Using two variants of a renal perfusion procedure, i.e. an ex 
vivo perfusion model in which all components were directly 
injected into the left kidney and an in vivo perfusion model in 
which the mAb was injected into the tail vein 1 hour after the 
renal perfusion of the nuclear components, a shift of the immune-
deposits was observed from the inner side of the capillary wall 
to the subepithelial space. It is likely that in the ex vivo 
perfusion experiments the administration of the anti-DNA mAb 
immediately after the perfusion of histones and DNA prevented a 
deeper penetration and aggregation of the nuclear components into 
the capillary wall. It is known that immune-aggregates formed on 
the cell membranes of endothelial cells are not stable and are 
rapidly shed into the circulation 32. The fact that in the in vivo 
perfusion model only immune-deposits were found in the 
subepithelial space of the glomerular capillary wall and not on 
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endothelial cells, is in line with this assumption. Furthermore 
we found in the in vivo perfusion experiments that the amount of 
DNA-anti-DNA mAb complexes in the mesangium was considerably less 
than in the ex vivo perfusion procedure suggesting a normal 
clearance in the mesangium for these complexes. 
Quite interestingly, high avid anti-DNA mAb, either bound to the 
glomerular capillary wall through histone/DNA particles or to the 
mesangium through DNA alone, were able to enhance the albumin 
excretion. Although these findings are based on a small number 
of animals and need to be extended, they suggest that high avid 
anti-DNA antibodies have a greater nephritogenic potential. Based 
on serum studies this assumption has been advocated previously 
5,33 
The results of the in vitro studies with GBM-loops were identical 
to the findings from the perfusion studies, with one exception. 
In vitro we found binding with mAb 42 to isolated GBM-loops 
preincubated with DNA alone, which is in line with studies in the 
literature which suggest that anti-DNA can bind to the GBM 
because of affinity of DNA for extra-cellular matrix components 
34,35
. Nevertheless, binding to the GBM itself via DNA alone could 
not be induced in the renal perfusion studies. This discrepancy 
between our in vitro and in vivo findings may be caused by 
contamination of the GBM-loops with histones released during the 
relatively harsh conditions used for isolation. As reported by 
Schmiedeke et al 2I, histones can bind with very high affinity to 
Heparin Sepharose, a GBM-like matrix, and this binding could only 
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be broken with 6 M guanidine-HCl. We used 3 M salt conditions in 
combination with DNase which removed DNA effectively from the 
GBM, but we cannot exclude that histones were still present. 
These histones can cause the subsequent binding of DNA. 
At present we are not able to define precisely which GBM 
constituent is responsible for the binding of histones and 
subsequently DNA and anti-DNA to the GBM. Based on our previous 
studies HS is a likely candidate for the histone binding in the 
GBM w·2021, which is further substantiated by the work of 
Schmiedeke et al 21·3*·37. However, our in vitro incubation studies 
with GBM-loops make it likely that other anionic sites are 
probably also involved. The relative harsh conditions used to 
prepare cell and DNA free GBM-loops led to a decrease of HS 
within the GBM, since staining with a monoclonal antibody towards 
HS became negative (data not shown). Despite this reduction of 
HS-associated anionic sites, we still found a strong binding of 
cationic ferritin to the isolated GBM-loops, indicating that 
other anionic sites were still present. These findings are in 
line with the observations of Bertolatus and Hunsicker 3e, who 
found that besides HS associated anionic sites other anionic 
sites like non HS associated carboxylgroups may be important for 
the net negative charge of the GBM. Preincubation of GBM-loops 
with cationic ferritin prevented subsequent histone/DNA binding 
(data not shown) which suggests that anionic sites in the GBM are 
responsible for the binding of histones. How DNA is trapped in 
the mesangium also needs further elucidation. A possible 
candidate responsible for DNA binding is fibronectin. It is known 
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that fibronectin is abundantly present in mesangial areas " and 
has a binding site for DNA ^ . In preliminary experiments we found 
in ELISA that DNA can bind to fibronectin and subsequently can 
cause the binding of anti-DNA mAb, while mAb alone did not bind 
to fibronectin (data not shown). Another mesangial matrix 
component which has been reported to bind DNA is collagen type 
V ". It is conceivable therefore that during passage of DNA from 
the capillary wall to the mesangium, DNA is bound to fibronectin 
and/or collagen type V and subsequently serves as a planted 
antigen for high avid anti-DNA antibodies. Both mechanisms of 
anti-DNA binding, via histones and DNA to the GBM and via DNA to 
the mesangium, seem to have nephritogenic potential because they 
both induced an increased albumin excretion. 
Our results indicate that histones play a crucial role in the 
deposition of anti-DNA in the glomerular capillary wall as seen 
in SLE nephritis, which is underlined by studies reporting the 
presence of histones in the immune deposits in kidneys of SLE 
mice 37 and in renal biopsies of SLE patients 42. These data are 
corroborated by studies which showed that positively charged 
molecules can act as planted antigen in the glomerulus for 
subsequent antibody binding and induction of proteinuria 43J'8. 
Recently it was shown that in the circulation of SLE patients DNA 
is present in association with histones 49. It remains to be 
determined whether the glomerular binding of anti-DNA is mediated 
via in situ immune complex formation or caused by the binding of 
circulating histone/DNA/anti-DNA complexes. A study from our 
laboratory in a small number of SLE patients seems in favor of 
83 
the last possibility, since we found anti-HS reactivity in the 
serum, caused by circulating histone/DNA/anti-DNA complexes, 
prior to the onset of SLE nephritis 50. In summary, this study 
confirms our previous findings that anti-DNA does not bind 
directly to renal antigens due to cross-reactions M H · 2 5 , but that 
the binding to the GBM is mediated via histone/DNA particles. 
Furthermore, we could show that anti-DNA can also bind to 
mesangial areas via DNA alone. Binding via both mechanisms can 
cause albuminuria and may be operative in the pathogenesis of SLE 
nephritis and might offer an explanation for the variable renal 
histopathology which is characteristically found in SLE 
nephritis. 
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ABSTRACT 
MRL/1 mice, with diffuse proliferative glomerulonephritis, and 
graft versus host (GVH) mice with membranous 
glomerulonephritis, are both regarded as models for human 
Systemic Lupus Erythematosus (SLE). To characterize the 
nephritogenic antibodies (Ab) in these two models, we analyzed 
the reactivities of Ab eluted from glomeruli towards 
components of the glomerular basement membrane (GBM) and 
nuclear antigens. We purified Ab from these eluates under high 
salt conditions to exclude the presence of antigens eventually 
bound to the Ab. Glomerular eluates of both GVH and MRL/1 mice 
showed nuclear staining and linear binding to GBM and tubular 
basement membranes (TBM) in the indirect immuno-fluorescence 
(IF) on normal mouse kidney. In ELISA both eluates reacted not 
only with DNA, but also with histones and laminin, an 
important component of the GBM. Reactivity with doublestranded 
DNA was also found in the Crithidia luciliae assay for both 
eluates. In vivo binding was determined by injection of 
eluates into control MRL/n and F1 hybrid mice. The GVH eluate 
showed linear binding to the GBM 1.5 h after injection which 
changed into a granular, membranous pattern after 5 days, as 
determined by IF and immuno-electron microscopy (IEM). The 
MRL/1 eluate also demonstrated linear binding to the GBM 1.5 h 
after i.v. injection, which had decreased after 5 days, but 
did not change into a granular pattern. We conclude that in 
these two models of SLE nephritis not only Ab to nuclear 
antigens (DNA and histones) but also Ab to laminin are 
involved. This latter Ab specificity has not been identified 
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before in renal or glomerular eluates obtained from diseased 
MRL/1 mice. 
INTRODUCTION 
Animal models resembling human SLE, such as the MRL/1 strain ' 
and mice suffering from chronic graft-versus-host (GVH) 
disease 2·3, are important tools in elucidating the pathogenesis 
of this autoimmune disease. Both MRL/1 and GVH mice produce 
autoantibodies similar to those found in human SLE iA and 
develop distinct forms of glomerulonephritis. As in human SLE, 
it has been assumed that glomerulonephritis in these models is 
initiated by the deposition of immune complexes 5. There are, 
however, differences between these two murine models with 
respect to the induction and the presumed pathogenesis of 
their autoimmune disease. 
The MRL/1 mice spontaneously develop an autoimmune disease 
which is characterized by a diffuse proliferative 
glomerulonephritis accompanied by a necrotizing vasculitis '. 
Glomerular lesions are characterized by the accumulation of 
monocytes and proliferation of both endothelial and mesangial 
cells with occasional crescent formation. Immunofluorescence 
studies reveal granular deposits of mouse IgG and C3 in the 
mesangium and along the capillary wall. Clinically, these 
animals develop proteinuria and a deterioration of kidney 
function between the age of 3 and 6 months. They usually die 
of renal failure between 5 and 6 months of age. 
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Chronic GVH disease is passively induced in non-irradiated 
normal hybrid mice after injection of semi-allogeneic parental 
lymphocytes 2·6. The major cause of death in chronic GVH disease 
is also a severe glomerulonephritis resulting in a nephrotic 
syndrome with hypoalbuminemia and ascites, which develops 
about 2 - 3 months after injection of the donor lymphocytes 2'6. 
Morphologically, the predominant renal lesion is a membranous 
glomerulonephritis 2. Two to three weeks after the induction of 
GVH disease a linear binding of antibodies to the GBM can be 
found, which changes into a granular membranous pattern, as 
revealed by IF and electron microscopy (EM), after 6 - 8 weeks 
7 
Although a variety of autoantibodies can be found in SLE 
patients and animals with SLE-like syndromes, antibodies (Ab) 
to DNA are considered to be specific for SLE 8 and are thought 
to play a pivotal role in the pathogenesis of the nephritis 
913
. The pathogenic role of anti-DNA Ab is supported by studies 
showing the presence of anti-DNA Ab in eluates obtained from 
kidneys or isolated glomeruli from SLE patients or animals 
9-ii,i4-i7 _ However, studies in murine models so far have only been 
carried out with eluates obtained from whole kidneys. This 
procedure leads to contamination with Ab bound to 
extraglomerular renal structures and the specificities in 
these whole-kidney or cortex eluates probably reflect more the 
Ab present in the circulation than those bound in the 
glomeruli ". We have successfully isolated glomeruli of 
affected kidneys from GVH and MRL/1 mice by an improved method 
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and have subsequently eluted Ab from these glomeruli. 
In this study we have tested the antigen specificities of the 
eluted antibodies by examining their reactivities to nuclear 
antigens, extracellular matrix components, and brush border 
antigens, several of which are also localized in cell 
membranes of glomerular epithelial cells. Furthermore, we 
determined the glomerular binding in vivo by injecting the 
eluates into normal mice. We found that antibodies from 
affected glomeruli of both SLE strains react with laminin, a 
component of the glomerular basement membranes and to two 
nuclear components, histone and DNA. 
MATERIALS AND METHODS 
Animals; C57B1/10 and DBA/2 mice were originally obtained from 
the Jackson Laboratory, Bar Harbor, Maine and were kept in our 
laboratory by continuous brother - sister matings. (DBA/2 χ 
C57B1/10)F1 hybrid mice were bred in the animal facilities of 
the University of Nijmegen. MRL/l (MRL Ipr/lpr) and MRL/n (MRL 
+/+) mice were bred from stock originally obtained via the 
Scripps Clinic and Research Foundation, La Jolla, CA, USA from 
the Jackson Laboratory. 
MRL/l mice; Blood was obtained from 60 MRL/l mice at the age 
between 5 and 6 months and pooled. Only mice with proteinuria 
were used for this study. Kidneys were infused with iron oxide 
(Fe304) via the aorta (see below) . From all individual mice a 
small piece of kidney was taken to study immune deposits in 
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the glomeruli by direct IF. The control group consisted of 30 
MRL/n mice at the age of 4 months. 
Induction of Graft Versus Host Disease; Sixty female (DBA/2 χ 
C57B1/10)F1 hybrids were injected intravenously with 1.8 χ io" 
lymphocytes from the thymus, spleen and abdominal lymph nodes 
of female DBA/2 mice at day 0 and day 5. At week 12 albumin 
excretion was measured in 18 h urine samples by a radial 
immunodiffusion technique ". Then, from all mice blood was 
obtained and kidneys were infused with iron oxide and checked 
for immune deposits as described above. The control group 
consisted of 30 untreated F, hybrid mice at the age of 3 
months. 
Isolation of mouse glomeruli: The isolation was carried out as 
described previously M. Briefly, mice were anaesthetized and 
the kidneys were perfused in situ with PBS via a catheter in 
the abdominal aorta until they visually blanched. 
Subsequently, 1 to 2 ml of a solution containing 12.5 mg/ml 
magnetic iron oxide (Гез04; BDH, Poole, UK) suspended in PBS 
was infused. The kidneys were removed and passed through a 90 
μη sieve. Then, the glomerular suspension was allowed to 
sediment (3x15 min) after which the supernatant was discarded. 
Subsequently glomeruli were resuspended in PBS and collected 
by use of a magnet (3x20 sec). The obtained material consisted 
of glomeruli for more than 95 %. 
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Elution of antibodies from glomeruli: Ab were first eluted 
from glomeruli by acid elution (0.12 M glycine-HCl, pH 2.8) 
for 2 h at room temperature. The glomerular suspension was 
then spun down (5 min, 100g) and a basic elution was performed 
for 2 h at room temperature (0.12 M glycine-NaOH, pH 12.0) 
also under continuous shaking. During the elution procedures 
the pH was readjusted to respectively pH 2.8 and pH 12.0. 
Finally, we performed an elution on the same glomerular 
suspension under high molar salt conditions (3M KSCN) for 2 h 
at room temperature. All steps were carried out in the 
presence of protease inhibitors (ImM PMSF, 0.05% NaAzide, 20mM 
EDTA and 100 KI units Trasylol) with continuous shaking. After 
elution the pH was immediately adjusted to 7.4 and, 
subsequently, eluates were dialyzed overnight at 40C against 
PBS containing protease inhibitors. Finally, eluates were 
concentrated on an Amicon YM50 filter to a final volume of 5 
ml and stored at 40C. The concentration of IgG in the eluates 
was determined by radial immunodiffusion using a mouse IgG 
standard and a goat anti-mouse IgG antiserum (heavy and light 
chain specific; Sigma, St. Louis, MO, U.S.A.) 
Purification of IgG under dissociative conditions: 
Previously we have found that the reactivity of autoantibodies 
can be disturbed by the presence of nuclear antigens complexed 
to the Ab 21·22. Therefore, we purified the eluted Ab under high 
molar salt conditions, as described previously, in order to 
remove complexed antigens 2I·22. Briefly, 2 ml of concentrated 
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eluate were diluted to a final volume of 14 ml in binding 
buffer containing 3 M NaCl, 1.5 M glycine-NaOH, pH 8.9. 
Subsequently, 0.5 ml of pre-swollen protein-Α Sepharose 
(Pharmacia, Uppsala, Sweden) was added and Ab were allowed to 
bind to protein-Α Sepharose for 1 h at room temperature. After 
centrifugation for 5 min at 100g, bound immunoglobulins were 
eluted from the protein-Α sepharose with 2 ml of 0.1 M citric 
acid pH 3.0, and after 10 min the protein-Α sepharose was spun 
down. The pH of the supernatant containing the purified IgG 
was immediately adjusted to pH 7.4 and thereafter the 
preparation was dialyzed against PBS containing protease 
inhibitors and stored at 4eC. 
Tests for antibody specificity 
Indirect IF: Antibody reactivity to renal structures, such as 
nuclei or GBM and TBM was determined with an indirect IF test 
on kidney slides of normal (C57B1/10 χ DBA2) F, or MRL/n mice. 
The titer (U/ml) was defined as the reciprocal of the highest 
dilution that still gave a positive staining. 
Anti-DNA antibody assays: Anti-DNA antibody activity was 
determined in both the anti-DNA ELISA 23 and the IF on 
Crithidia luciliae ^ as described previously. 
Anti-histone ELISA: Calf thymus histones, either total 
histones or histone subfractions (Boehringer, Mannheim, 
Germany) were coated overnight to polystyrene microtiter 
plates (Greiner, Alphen a/d Rijn, The Netherlands) in 20 mM 
carbonate buffer pH 9.6 (1 ßg/vell). The further procedure was 
identical to the anti-DNA ELISA with the exception that the 
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peroxidase-conjugated rabbit anti-mouse IgG (ICN 
ImmunoBiologicals, Lisle, IL, USA) was diluted in PBS-gelatin 
containing 5% normal rabbit serum to prevent non-specific 
binding to histones. 
Anti-GBM components ELISA: Polystyrene microtiter plates 
(Greiner) were coated overnight at room temperature with 1 
μg/well heparan sulphate proteoglycan (HSPG) isolated from 
human kidneys as described previously M, mouse fibronectin 
(Calbiochem, La Jolla, Ca) in 20 mM carbonate pH 9.6, mouse 
collagen type IV (Collaborative Research Incorporated, 
Bedford, MA) in PBS or mouse laminin (Gibco, New York), and 
laminin fragments E3, E4, E8, PI and ElX-Nd (which is a 
complex of PI, E4 and nidogen) in PBS, which were a kind gift 
of Dr. A. Sonnenberg and prepared as described elsewere 26. 
Thereafter, the ELISA was carried out as described previously 
25
 except for the ELISA with laminin fragments, in which 
alkaline phosphatase-conjugated rabbit anti-mouse IgG 
(Jackson, West Grove, PA, USA) was used. Phosphatase was 
visualized by incubation with p-nitro-phenyl phosphate. 
Anti-Brush Border ELISA: Brush Border (BB) membranes were 
prepared from normal mouse kidneys according to the method 
described by Malathi et al я. BB membranes were solubilized 
with 1% Sodium deoxycholate in Tris-HCl buffer pH 8.6 for 1 
hour at room temperature. Insoluble material was spun down for 
30 min at 100,000g and the supernatant was dialyzed against 
0.1% Sodium deoxycholate in Tris-HCl buffer pH 8.6. The 
obtained BB extract was coated overnight at room temperature 
(1 Mg/well diluted in PBS) to polystyrene microtiter plates 
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(Greiner). Further procedures were identical to the anti-GBM 
components ELISA. 
The titer (U/ml) in ELISA was defined as the reciprocal of the 
dilution of the sample giving 50% of the maximal absorption at 
450 nm. In all ELISA assays Ab were also tested on wells in 
which during the coating procedure buffer without antigen was 
used. The enrichment of antibody specificities in the 
glomeruli was determined by comparing the antibody 
reactivities expressed as U/mg IgG of the sera with those of 
the glomerular eluates. 
In vivo binding of eluted antibodies: Hundred pq IgG of GVH 
eluate, dissolved in 0.8 ml PBS, were injected intravenously 
into normal (C57B1/10 χ DBA/2)Fl hybrid mice, while 40 μg IgG 
of MRL/1 eluate in 0.8 ml PBS were injected i.v. into MRL/n 
mice. One and half hour and 5 days after injection mice were 
sacrificed and the kidneys processed for IF and IEM. The 
abdominal aorta was cannulated retrogradely, ligated above the 
renal arteries, and subsequently both kidneys were perfused 
with PBS for 5 min. The right kidney was then removed and 
processed for IF, and the left kidney was used for (IEM) after 
perfusion with a mixture of periodate, lysine, and 2% 
paraformaldehyde (PLP) during 10 min. Thereafter, the kidney 
was removed and small pieces of renal cortex were immersed in 
PLP for an additional 3 hours. 
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Immuno-histoloqy. 
For in vitro binding studies 2 μια cryostat sections from 
normal Fl hybrid and MRL/n kidneys were incubated with the 
eluted Ab and with sera from GVH, MRL/1, Fl hybrids and MRL/n 
mice for 30 min in twofold dilution steps. After rinsing in 
PBS, the sections were subsequently incubated with a F(ab)2 
FITC-labeled sheep anti-mouse IgG (Cappel-Organon Technika NV, 
Turnhout, Belgium) for 30 min. The renal binding of the eluted 
Ab after intravenous injection into Fl hybrids and MRL/n mice 
was studied by incubation of cryostat sections with FITC-
labeled sheep anti-mouse IgG as described above. After rinsing 
in PBS, all sections were embedded in Aguamount (BDH Ltd., 
Poole, England) and examined with a Leitz fluorescence 
microscope equipped with a Ploemopak epiillumination. 
For the indirect IEM the left kidney from a normal (C57B1/10 χ 
DBA/2)Fl hybrid mouse and from a MRL/n mouse was fixed with 
PLP as described above. Binding of the eluted Ab to renal 
structures and their localization in the glomerulus after i.v. 
injection were both visualized by immunoperoxidase labeling 
on 20 μτα frozen sections. The small fragments of renal cortex 
fixed with PLP were rinsed several times in PBS, cryoprotected 
by immersion in 2.3 M sucrose buffered with 0.1 M phosphate 
buffer, pH 7.2, for 1 hour, and then frozen in liquid 
nitrogen. For the immunoperoxidase labeling 20 μτα sections 
were rinsed in PBS for 1 hour, and incubated with the eluted 
Ab after several washes with PBS followed by incubation with a 
peroxidase labeled rabbit anti-mouse IgG, diluted 1:20 
100 
(Dakopatt, Copenhagen, Denmark). For the detection of eluted 
mouse IgGs bound to the glomeruli after injection into the 
mouse, only the latter incubation step with the peroxidase 
labeled rabbit anti-mouse IgG was performed. After 3 washes in 
PBS, the sections were preincubated in diaminobenzidine (DAB) 
medium containing 0.6% Tris for 10-15 min, followed by DAB 
with addition of H202 to a final concentration of 0.001%. The 
sections were washed in distilled water, postfixed in 0.1 M 
phosphate-buffered 2% 0s04 for 30 min at room temperature, 
dehydrated, and embedded in Epon 812. Thin sections were 
prepared on a LKB ultratome, and examined unstained in an 
electron microscope (Philips 300, Eindhoven, The Netherlands). 
RESULTS 
Antibody specificities present in pooled sera from MRL/1 and 
GVH mice 
The MRL/1 serum, containing 80 mg IgG/ral showed a strong, 
homogeneous nuclear staining (ANA) in the indirect IF on a 
normal MRL/n kidney. All other renal structures, such as the 
GBM, TBM and BB were negative (Fig.lA). In ELISA, it reacted 
with DNA, histones and weakly with BB antigens (Table 1). The 
presence of anti-DNA Ab in the MRL/1 serum could also be 
demonstrated with the Crithidia luciliae assay. After 
purification of the MRL/1 serum under high molar salt 
conditions to remove potentially bound antigens, the 
reactivity in the indirect IF was identical to that in the 
unpurified sample and it remained positive in the Crithidia 
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Figure 1 : The in vitro binding to kidney sections of control mice of sera 
and glomerular eluates from MRL/1 and GVH mice as determined with indirect 
IF. The MRL/1 serum only showed nuclear staining (A) whereas linear 
staining of GBM and TBM besides ANA staining was detected with the MRL/1 
eluate (B). With the GVH serum we obtained ANA staining as well as staining 
of the BB of proximal tubules (C), while the GVH eluate showed a staining 
pattern identical to the MRL/1 eluate: linear GBM/TBM and ANA staining (D) . 
(A) 800x; (B) SSOx; (C) SOOx; (D) BOOx. 
102 
assay. In ELISA the purified serum showed an unaltered binding 
to DNA and histones, but the reactivity to BB antigens had 
disappeared. 
In the GVH serum, that contained 20 mg IgG/ml, we could detect 
antinuclear (ANA) and anti-BB antibodies with indirect IF on a 
normal Tl hybrid kidney (Fig.1С). The majority of the 
antinuclear antibodies was not directed against DNA, since we 
found hardly any reactivity in the anti-DNA ELISA and no 
reactivity in the Crithidia luciliae assay. Furthermore, we 
could not detect anti-BB antibodies with the ELISA, suggesting 
that the anti-BB antibodies observed in the indirect IF are 
not directed against the detergent solubilized BB antigens 
that were used in the ELISA technique. The purified GVH serum 
showed similar reactivities in the indirect IF and ELISA, 
except for the binding to histones in ELISA, which became 
weakly positive after purification (6 U/mg). 
No reactivity could be detected with the pooled sera from 
MRL/n or normal Fl hybrid mice in any of the assays. 
Immunoglobulin content of eluates obtained from glomeruli of 
MRL/1 and GVH mice 
MRL/1 glomeruli used for the elution studies contained 
variable amounts of IgG in the mesangium or along the 
capillary wall as revealed by IF. GVH mice had heavy IgG 
deposits along the capillary wall in a typical membranous 
pattern with variable mesangial deposits. The amount of IgG 
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deposited in glomeruli of MRL/1 mice was in general less than 
that in glomeruli of GVH mice. Glomeruli of MRL/n and Fl 
hybrid control mice contained only moderate amounts of IgG 
localized mainly in the mesangium as is observed in many 
normal mouse strains. After concentration the MRL/1 eluate 
obtained by acid elution contained 51 pq IgG/ml. The total 
yield was 7 ßg IgG/g kidney. The GVH eluate obtained by acid 
elution contained 718 /xg IgG/ml after concentration with a 
yield of 103 ßg IgG/g kidney. Subsequent elutions with a basic 
and a high molar buffer did not extract additional IgG from 
the glomerular suspension and eluates did not show any 
reactivity in the assays. Therefore, only the results of the 
acid eluates will be described. The higher yield of the GVH 
eluate is in accordance with the findings with indirect IF 
which showed that the GVH glomeruli contained much more Ig 
deposits than the MRL/1 glomeruli. After purification of both 
acid eluates under high molar salt conditions we recovered 20 
μg IgG/ml from the MRL/1 eluate and 116 ßg IgG/ml from the GVH 
eluate. The acid eluates from the MRL/n and Fl hybrid control 
mice did not contain detectable IgG. 
Binding of MRL/1 and GVH eluates to normal mouse kidneys 
With indirect IF on kidney sections of a control MRL/n mouse 
the MRL/1 eluate showed a strong linear binding to the GBM and 
TBM (Fig.IB). Besides the predominant staining of basement 
membranes a strong homogeneous nuclear staining (ANA) was 
seen. The Ab eluted from GVH mice also bound linearly to the 
GBM and TBM in indirect IF on kidney sections of a control Fl 
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hybrid mouse and showed in addition ANA staining (Fig.ID). 
Staining of the BB of proximal tubular cells was not observed. 
Purification of IgG under dissociating conditions did not 
alter the binding pattern of the eluates. The Ab eluted from 
glomeruli of MRL/n or control Fl hybrid mice did not cause any 
staining of mouse renal structures. In indirect IEM both SLE 
eluates diffusely stained the GBM along with the cell 
membranes of the epithelia and to a lesser extent of the 
endothelia (Fig.5). Nuclei of cells damaged by the technical 
procedure also stained (not shown). 
Antigen specificity of MRL/1 and GVH eluates 
To specify more precisely the reactivities of the eluted 
antibodies as observed in the indirect IF we tested both 
eluates in ELISA for binding to nuclear antigens and GBM 
components. Both eluates contained antibodies directed against 
DNA and histones. The presence of anti-DNA antibodies was 
confirmed by the Crithidia luciliae assay, which detects 
highly avid anti-DNA antibodies. It is noteworthy that the 
MRL/1 eluate showed a much higher reactivity in this assay 
than the GVH eluate (Table 1) . These antibody specificities 
were also found in the eluates after purification (Fig.2). 
When tested on histone subfractions, the purified MRL/1 eluate 
reacted with subfractions H2a, H3 and H4 while the GVH eluate 
reacted with all histone subfractions (Fig.3). In addition 
both the unpurified and the purified eluates showed reactivity 
with laminin (Table 1, Fig.2). When the purified eluates were 
tested against enzymatically produced fragments of the laminin 
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Table 1. 
Antibody reactivity expressed in U/mg Ig of serum compared 
to eluate in the various assays.* 
MRL/1 GVH 
serum eluate serum eluate 
Indirect IF 
ANA 128 628 256 128 
GBM/TBM - 628 - 128 
BB 1 - 32 
Crithidia luciliae 8 118 - 16 
ELIBA 
DNA 
histones 
1aminin 
HSPG 
Collagen IV 
Fibronectin 
BB 
* Similar resulte were obtained with purified sera and eluates, 
except for the data Indicated with asterisks. 
** No reactivity could be detected after purification of IgG under 
dissociating conditions. 
*** After purification reactivity became 6 Ό/mg. 
12 
64 
-
-
1** 
1524 
20 
20 
-
_ 
2 
-*** 
-
-
_ 
750 
33 
33 
3 * * 
1** 
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molecule, they showed reactivity particularly with the E3 and 
E4 fragments but also to a lesser extent with the other 
laminin fragments (Fig.4). The higher signals in the ELISA 
assays with the GVH eluate can be explained by the higher IgG 
content of this eluate. Furthermore, the GVH eluate also 
showed some reactivity to collagen IV and BB antigens (Table 
1) , however this binding disappeared after purification of the 
eluate (Fig.2) indicating that the reactivity of the 
unpurified antibodies was probably due to a false positive 
reaction caused by antigens complexed to the antibodies. The 
MRL/n and control Fl hybrid eluate were negative in all these 
assays. 
On comparing the antibody reactivities, expressed as U/mg IgG 
of serum with the glomerular eluate, it is obvious that 
antibodies to DNA and antibodies to laminin are greatly 
enriched in the glomeruli of MRL/1 mice (Table 1) . Antibodies 
to histones, although present in both the serum and glomerular 
eluate, did not accumulate specifically in the glomeruli. In 
the glomeruli of the GVH mice there is a greatly enhanced 
accumulation of antibodies directed against DNA, histones and 
laminin. 
107 
% binding 
100 • S MRL/I 
CD а н 
DNA h letones laminln collagen IV HSPQ flbronectin BB 
Figure 2: Reactivity of the eluates in ELISA after purification under 
dissociating conditions. The reactivity of the purified eluate is expressed 
as percentage binding of the reactivity of the unpurified eluate, which was 
set to 100*. 
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Figure 3: Reactivity in ELISA of purified eluates with total histones 
(Hmix) and with the individual histone subfractions. In both eluates anti-
histone Ab are present. In the GVH eluate reactivity to all histone 
subfractions is detected with the highest reactivity directed to histone 
fractions H2a, H3 and H4; in the HRL/1 eluate only reactivity to histone 
fractions H2a, H3 and H4 is found. The higher reactivity of the purified 
OVH eluate (see also Fig.4) can be explained by the higher Ig content of 
this eluate compared to the purified HRL/1 eluate. Ho reactivity with 
histones was found with the purified control eluates from HRL/n or control 
Fl mice. 
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Figure 4: Reactivity in ELISA of purified eluates with the laminin-nidogen 
complex (LN-Nd) and various laminin fragments (PI, E3, E4 and ElX-Nd, the 
latter is a complex of PI, E4 and nidogen). In both purified eluates Ab 
directed to laminin are present. Although reactivity to all laminin 
fragments can be detected, the highest reactivity is found with fragments 
E3 and E4. No binding was observed with the purified control eluates. 
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Figure 5: In the indirect IEM on normal mouse kidney both the MRL/1 eluate 
(A) and the GVH eluate (B) show a diffuse staining of the GBM and in 
addition stain the cell membranes of glomerular epithelial cells and to a 
iesser extent of the endothelial cells. 
Ill 
In vivo binding of the MRL/1 and GVH eluate 
Ninety minutes after injection of the eluted MRL/1 antibodies 
into control MRL/n mice a linear staining of the GBM was 
found. In addition a homogeneous staining of the knob-like GBM 
extensions located subepithelially, which are a normal 
constituent of the GBM in most mouse strains, could be 
observed by IF (Fig.6A). After 5 days the linear staining had 
considerably decreased and had not changed into the granular, 
membranous pattern that was seen after injection of the GVH 
eluate (see below) . With the IEM technique the same binding 
patterns were observed (Fig.7A). A homogeneous binding was 
present predominantly located in the GBM with its 
subepithelial extensions. The cell membranes of the glomerular 
visceral epithelial and endothelial cells adjacent to the GBM 
were also stained. At day 5 the GBM staining had decreased 
considerably. 
Intravenous injection of GVH eluate into control Fl mice 
resulted in a strong linear binding to the GBM as seen by IF 
after 1.5h (Fig.6C). By IEM the Ab were predominantly located 
diffusely within the GBM and to a lesser degree on the 
adjacent cell membranes of endothelia and epithelia (Fig.7C) 
of the glomerular capillary wall. They were hardly detectable 
in the knob-like extensions on the epithelial side of the GBM. 
This pattern was somewhat different from the MRL/1 eluate 
which bound not only linearly to the GBM proper, but also to 
these subepithelially located GBM-extensions. At day 5 after 
injection the Ab had mostly aggregated into fine granular 
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figure б; The in vivo binding of the eluates to renal structures after i.v. 
injection into normal mice revealed by a direct IF. The MRL/l eluate show 
linear binding to the GBM 1.5 h after injection (A). After i.v. injection 
of control eluate no binding in the glomerulus was detected after 1.5 h or 
at day 5 (B). The GVH eluate also shows linear binding to the GBM 1.5 h 
after injection (C), however this binding had changed into a granular, 
membranous pattern at day 5 (D). 
(A) 1024x; (B) 640x; (C) 800x; (D) 800x. 
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Figure 7: IEM photomicrographs of the in vivo binding of the glomerular 
eluates of MRL/1 and GVH mice. After injection of the MRL/1 eluate a 
homogeneous binding is observed predominantly located in the GBM with its 
knob-like extensions localized at the epithelial side, along with staining 
of the cell membranes adjacent to the GBM (A,inset). After injection of 
control eluates no staining of the GBM could be observed (B). Strong linear 
binding to the GBM was seen 1.5 h after injection of the GVH eluate and to 
a 2esser degree to the adjacent cell membranes of endothelial and 
epithelial cells (C) . At day 5 after injection of the GVH eluate the 
deposits were mostly seen as aggegates in the slit pores or under the 
visceral epithelial cells (D) as well as on the knob-like epithelial 
extensions of the GBM (E). 
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deposits along the capillary wall in a characteristic 
membranous pattern as seen in IF (Fig.6D). Also by IEM the 
deposits were mostly seen in aggregates in the slit pores or 
under the visceral epithelial cells with some residual binding 
to the GBM (Fig.7D). After the i.v. injection of Ab eluted 
from control MRL/n and F, hybrid mice there was no glomerular 
binding at 1.5h and 5 days after i.v. injection (Fig.6B). 
DISCUSSION 
It is generally assumed that glomerulonephritis occurring in 
human SLE or in SLE-prone mice is induced by the deposition of 
Ab, and that anti-DNA Ab are responsible for the glomerular 
damage in this disease 28. However passive transfer of 
polyclonal Ab to DNA obtained from sera or kidney eluates of 
affected humans or mice, as well as the injection of 
monoclonal anti-DNA Ab into normal animals, mostly failed to 
show binding in the glomerulus, or at best showed only 
localization in the mesangium I3·2'. To address the question of 
whether additional Ab specificities besides anti-DNA are 
involved in the induction of SLE glomerulonephritis, we 
characterized in a more direct approach the specificities of 
the Ab bound in the glomeruli, thus circumventing the 
cumbersome determination of the many Ab specificities present 
in the serum of which the nephritogenic potential is difficult 
to prove. Both in the MRL/1 eluate and in the GVH eluate we 
could detect Ab not only to two nuclear antigens, i.e. 
histones and DNA, which are both components of the nucleosome, 
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but also to laminin which is present in nearly all basement 
membranes. This latter Ab specificity has not been identified 
before in renal or glomerular eluates obtained from MRL/1 
mice, we also were unable to detect it in sera or whole kidney 
eluates of diseased MRL/1 mice (data not shown). 
Our findings confirm the results from previous studies based 
on eluates from whole kidneys that anti-DNA Ab are present in 
glomeruli of SLE-prone mice 14,16. Until recently it has remained 
unclear how anti-DNA Ab become trapped in the glomerular tuft. 
We have reported that anti-DNA Ab can bind to negatively 
charged components of the GBM, probably heparan sulphate, via 
DNA/histone complexes и. The role of histones in this binding 
mechanism was elucidated by Schmiedeke et al who showed that 
histones are able to bind to the GBM, due to charge 
interactions, and that they can act as planted antigen for 
anti-histone Ab эо. In addition, they showed that histones 
fixed to the GBM can enhance the glomerular binding of DNA, 
which then can serve as planted antigen for anti-DNA Ab 3,. 
Similar results were recently obtained in our laboratory with 
anti-DNA monoclonal antibodies in unilateral renal perfusion 
studies in the rat (Termaat et al, manuscript in preparation). 
This has important implications for previous studies which 
reported that anti-DNA can bind directly to renal antigens by 
a cross-reacting mechanism 13·I7·2,·И. The results of these studies 
should now be interpreted with caution, since the anti-DNA Ab 
were not purified under dissociating conditions and therefore 
binding may have been caused by nucleosomes complexed to these 
116 
Ab. In addition, the polyclonal IgG isolated from sera of 
patients with SLE nephritis by Raz et al 13 may have contained 
anti-laminin Ab that could have contributed to the renal 
damage observed in their perfusion experiments. It has been 
stated earlier that the presence of anti-DNA Ab with high 
avidity in sera is associated with the occurrence of a 
proliferative glomerulonephritis, whereas anti-DNA Ab with low 
avidity are more related to the development of a membranous 
glomerulonephritis 33. The reactivity in the Crithidia luciliae 
assay which detects anti-DNA Ab with a higher avidity than the 
ELISA *·, suggests that the MRL/1 eluate contained anti-DNA Ab 
with higher avidities than the GVH eluate that mainly 
contained Ab binding only to DNA in ELISA. These differences 
in avidity may account for the different forms of 
glomerulonephritis that develop in these two models. In both 
eluates anti-histone Ab were also present. These Ab have been 
reported to be present in other SLE-prone mice and in humans 
in whom an association of anti-histone Ab was suggested with a 
more severe form of nephritis (reviewed in 35) . In the two 
eluates the highest reactivity was detected in the histone 
subfractions H2a, H3 and H4, which have been shown to bind 
with high affinity to the GBM 30. Schmiedeke et al have 
confirmed the presence of these histone subfractions in the 
immune complexes in kidneys of GVH and NZB/W mice, another SLE 
mouse strain ", 
The presence of anti-laminin Ab in renal eluates of GVH mice 
has been reported recently 7·17·38. Anti-laminin Ab have also been 
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demonstrated in the sera of MRL/1 mice concomitant with the 
development of nephritis э', but so far have not been studied 
in renal or glomerular eluates from these mice. In the past, 
Ab to laminin have been found in different models of 
experimental nephritis 4<M4. In addition antibodies against 
laminin are described to be present in sera from patients 
suffering from various diseases ^5·4', mostly in combination with 
Ab to other basement membrane components such as collagen type 
IV and nidogen. However, previous studies exploring the 
nephritogenic potential of anti-laminin Ab have shown no or 
only mild effects after intravenous injection into rats or 
mice 5 0· 5 1. Only slight basement membrane changes and a mild 
proteinuria have been observed in the autologous phase. The 
lack of nephritogenic effect may be explained either by 
insufficient amounts of Ab bound to the GBM to fix complement 
or by an inability of these Ab to activate complement. 
Heterologous anti-laminin Ab are indeed able to induce 
glomerular injury and proteinuria when there is a focused, 
amplified, and complement dependent immune attack on laminin 
localized in the GBM 52. 
Laminin is a large glycoprotein composed of many distinct 
domains with different structures and functions 53. Therefore, 
differences in epitope specificities of anti-laminin Ab have 
to be taken in to account when explaining the nephritogenic 
potential of these Ab. One report specified more precisely the 
epitope reactivity and nephritogenic potential of mAb to 
laminin derived from mercury treated DZB rats with an 
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autoimmune membranous glomerulonephritis и. It demonstrated 
reactivity to the P-l fragment of laminin, which contains a 
cell adhesion site and it could induce proteinuria when 
injected into normal rats. We have also tested the 
reactivities of the eluates with several laminin fragments 
known to have different functions. The Ab eluted from GVH mice 
showed reactivity to all laminin fragments with the highest 
binding to the E3 and E4 fragments. The E3 fragment has been 
identified as a heparin binding domain involved in the cell 
attachment via proteoglycans, while the E4 fragment is 
involved in the inhibition of the aggregation of laminin 53. 
Although to a lesser extent, the same reactivities to the E3 
and E4 fragments could also be recognized within the MRL/1 
eluate, based on these results we cannot define the epitope 
specificity of the nephritogenic anti-laminin antibodies in 
these two SLE models. Further studies are needed to elucidate 
the contribution of these anti-laminin Ab in the development 
of the nephritis in these two models. 
Transferring the GVH eluate to normal mice led to an initial 
linear binding of Ab to the GBM which changed into a 
characteristic membranous pattern with subepithelial deposits 
within 5 days. A similar transition occurs in GVH mice and in 
certain rat strains with mercury-induced glomerulonephritis 
and nicely mimics the binding kinetics of anti-laminin Ab as 
demonstrated in the rat 55. However, the linear binding of the 
MRL/1 eluate to the GBM after i.v. injection remained 
unchanged, fit this moment we can only speculate about this 
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discrepancy in the in vivo effects of the two eluates. The Ab 
may recognize different epitopes on laminin not yet detected 
by our ELISA with laminin fragments, or may bind to yet 
unidentified components of the GBM. It was recently proposed, 
that the brush border hydrolase dipeptidyl peptidase IV (DPP 
IV) may be one of the nephritogenic targets in the GVH disease 
in addition to laminin 37. However, we were not able to confirm 
this observation since we never observed any binding to the 
brush border of the proximal tubules in the indirect IF and 
IBM. The very low binding of the unpurified eluates in the BB 
ELISA, became negative after purification of the eluted Ab 
under dissociative conditions. This suggests that the binding 
of Ab in this ELISA is not direct, but is probably caused by 
the presence of complexed Ab as we have reported for 
unpurified culture supernatants 22. Bruijn et al used 
unpurified glomerular eluates for their studies in IF and 
ELISA, while their transfer studies showing the nephritogenic 
potential of anti-DPP IV Ab were performed with Ab purified 
from sera that contained also anti-laminin Ab. 
In conclusion we have shown in this study that the Ab bound to 
the glomeruli of GVH and MRL/1 mice with SLE-like syndromes 
are directed to histones, DNA and laminin. The question 
whether these Ab have an equal contribution to the development 
of glomerulonephritis in these two models or whether other 
antigens are also involved has not been resolved in this study 
and needs further examination. A nephritogenic potential of 
anti-laminin Ab seems likely from the results obtained in 
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other models. With respect to the Ab directed against nuclear 
antigens, it has been advocated that especially anti-DNA Ab 
play a role in the induction of glomerular injury although 
experimental evidence has so far been lacking. Preliminary 
results from our laboratory obtained with renal perfusion 
studies in the rat, as mentioned earlier, indicate that 
monoclonal anti-DNA antibodies can bind to the GBM via DNA and 
histones and can induce increased albumin excretion 
(manuscript in preparation) . It is very likely that the renal 
damage is the result of a combined effect of the individual 
Ab, possibly acting at different time points during the 
disease. We have only studied one time point relatively late 
in the development of the disease. Attempts to elute Ab at an 
earlier phase of the disease failed to extract a sufficient 
amount of Ab to do experiments. Finally, whether anti-histone 
or anti-laminin Ab are also involved in the pathogenesis of 
SLE nephritis in humans remains to be investigated. 
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CHAPTERS 
Summary 

SUMMARY 
The presence of antibodies to doublestranded DNA (anti-DNA) is 
regarded as the major serological marker of the autoimmune 
disease Systemic Lupus Erythematosus (SLE) and it is assumed 
that these antibodies play a key role in the development of 
the various disease manifestations. In this study the role of 
anti-DNA antibodies in the pathogenesis of SLE nephritis was 
investigated by studying the in vitro and in vivo binding of 
anti-DNA antibodies to glomerular components. Previous work 
from our group has shown that anti-DNA antibodies can 
crossreact with heparan sulphate (HS). Initial studies, 
described in chapter 2, seemed to underline our concept that 
anti-DNA antibodies could bind directly to HS. Both polyclonal 
and monoclonal anti-DNA antibodies bound not only to HS, but 
also to heparan sulphate proteoglycan (HSPG), the native 
molecule in the glomerular basement membrane (GBM) carrying 
the HS molecule. Furthermore, we found that anti-DNA 
monoclonal antibodies (mAb) could bind in vitro to isolated 
GBM-loops. The binding of anti-DNA to HS, to HSPG and to GBM-
loops could be inhibited by DNA in a dose-dependent manner. 
The anti-DNA binding to the GBM was inhibited by cationic 
ferritin and was partly reduced by pretreatment of the GBM by 
the HS degrading enzyme heparitinase. These findings supported 
the idea that anionic structures in the GBM, including HS, are 
important for the binding of anti-DNA to the GBM. Based on 
these findings we postulated that binding of anti-DNA 
antibodies to HS in the GBM is an important immunopathological 
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event in the development of SLE nephritis. 
When the crossreactive binding of anti-DNA with HS was studied 
in more detail using mAb (Chapter 3), we found that after 
purification under dissociating conditions all mAb completely 
lost their binding capacity to HS and HSPG. It appeared that 
the binding of anti-DNA to HS and HSPG was not due to a direct 
crossreactive binding, but was mediated via an intermediate 
ligand containing both DNA and histones. Based on these 
studies we had to readjust our initial concept of direct 
crossreactive binding of anti-DNA to HS and a new hypothesis 
for the in vivo glomerular binding of anti-DNA antibodies was 
formulated: anti-DNA antibodies can form immune complexes with 
DNA/histone particles and bind to the GBM through the interac-
tion of histones with HS (Chapter 4). 
The binding of anti-DNA to HS seems to have clinical 
relevance, since we found an association between anti-heparan 
sulphate reactivity in sera of SLE patients and the 
development of diffuse proliferative glomerulonephritis 
(Chapter 5) . Although it is assumed that high levels of anti-
DNA measured in the Farr assay, which exclusively detects 
antibodies with high avidity for doublestranded DNA, correlate 
with the development of renal disease, we found no correlation 
between reactivity in the anti-HS ELISA and anti-DNA levels 
measured in the Farr assay. However, we never observed anti-HS 
reactivity in Farr assay negative sera. This indicates that 
only a subpopulation of anti-DNA antibodies can bind to HS. 
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Since we reported that the binding of anti-DNA mAb to HS is 
mediated via DNA/histone particles, we had to verify whether 
the observed HS binding in the sera was not the result of 
histone/DNA/anti-DNA complexes that were formed during 
clotting of the blood samples. Similar anti-HS reactivities 
were found in simultaneously collected serum and plasma 
samples. Purification under dissociating conditions 
significantly decreased the anti-HS reactivity (>70%) of both 
the serum and the plasma samples. From these results it is 
concluded that the HS ELISA can detect nephritogenic anti-DNA 
antibodies complexed to nucleosomal material in the 
circulation of SLE patients before the onset or exacerbation 
of nephritis. Therefore, not the presence of high avidity 
anti-DNA antibodies by itself but the presence of 
histone/DNA/anti-DNA complexes in serum or plasma of SLE 
patients may identify patients at risk for the development of 
renal disease. 
Our new hypothesis concerning the mechanism of immune complex 
formation of anti-DNA antibodies in the glomerulus is 
corroborated by renal perfusion studies in the rat which show 
that the binding of anti-DNA to the GBM in tfivo is not due to 
direct binding of anti-DNA, but is mediated via histones and 
DNA (Chapter 6). In addition, we found a second mechanism of 
glomerular binding of anti-DNA that was only observed with a 
mAb with high avidity for doublestranded DNA. This binding was 
strictly confined to mesangial areas and was mediated by DNA 
alone. Binding via both mechanisms caused an increased urinary 
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albumin excretion. Therefore, it is likely that both 
mechanisms of anti-DNA deposition are involved in the 
pathogenesis of SLE nephritis. 
To investigate whether similar mechanisms are operative in SLE 
nephritis, we characterized the nephritogenic antibodies in 
two murine models of SLE nephritis: MRL/1 mice with diffuse 
proliferative glomerulonephritis, and graft versus host (GVH) 
mice with membranous glomerulonephritis (Chapter 7) . We 
analyzed the reactivities of Ab eluted from glomeruli of 
diseased kidneys to nuclear antigens and to intrinsic 
components of the GBM. Besides anti-DNA antibodies, we could 
identify antibodies to histones and to laminin in the eluates 
of glomeruli. Based on our results obtained in the renal 
perfusion studies it is likely that histones can act as 
planted antigens for anti-histone antibodies and it confirms 
that nucleosomes are involved in the deposition of antibodies 
in the glomerulus. Beside these two different anti-nuclear 
antibodies, which can bind indirectly to glomerular 
structures, also direct binding of antibodies to laminin, 
another important component of the GBM, may be involved in the 
pathogenesis of SLE nephritis. Whether anti-histone and anti-
laminin antibodies are, beside anti-DNA, also involved in the 
development of lupus nephritis in humans, remains to be 
investigated. These findings however, may have important 
implications for understanding the mechanism responsible for 
the renal injury in SLE patients. 
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SAMENVATTING 
Antistoffen tegen dubbelstrengs DNA (anti-DNA) zijn kenmerkend 
voor de auto-immuunziekte Systemische Lupus Erythematodes 
(SLE) . Men neemt aan dat deze antistoffen een rol spelen bij 
het ontstaan van de verschillende ziekteverschijnselen, met 
name bij het ontstaan van nefritis. In deze studie werd de rol 
van anti-DNA antistoffen in de Pathogenese van SLE nefritis 
onderzocht. Hiertoe werd de in vitro en in vivo binding van 
anti-DNA antistoffen aan componenten van de glomerulus (het 
filtratie orgaan in de nier) bestudeerd. Eerder onderzoek 
afkomstig uit onze groep toonde aan dat anti-DNA antistoffen 
kunnen kruisreageren met heparan sulfaat (HS), een van deze 
glomerulaire componenten. Aanvankelijk leken de studies 
beschreven in hoofdstuk 2 het concept te ondersteunen dat 
anti-DNA antistoffen direct kunnen binden aan HS. Zowel poly-
klonale als monoklonale anti-DNA antistoffen bonden niet 
alleen aan HS, maar ook aan heparan sulfaat proteoglycaan 
(HSPG), het molekuul in de glomerulaire basaal membraan (GBM) 
waarvan het HS molekuul deel uitmaakt. Bovendien hebben we 
gevonden dat monoklonale anti-DNA antistoffen in vitro kunnen 
binden aan geïsoleerde GBM. De binding van anti-DNA 
antistoffen aan HS, aan HSPG en aan de GBM kon op een dosis-
afhankelijke manier geremd worden door DNA. De binding van 
anti-DNA antistoffen aan de GBM werd eveneens geremd door 
cationisch ferritine, en nam gedeeltelijk af na voor-
behandeling van de GBM met heparitinase (een enzym dat HS 
afbreekt). Deze bevindingen ondersteunen het idee dat 
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anionische structuren in de GBM, waaronder HS, een rol spelen 
bij de binding van anti-DNA antistoffen aan de GBM. Uitgaande 
van deze bevindingen postuleerden we dat binding van anti-DNA 
antistoffen aan HS in de GBM een belangrijke stap is in de 
ontwikkeling van SLE nefritis. 
Echter, opzuivering van monoklonale anti-DNA antistoffen onder 
dissociatieve condities toonde aan dat alle monoklonalen hun 
vermogen tot binding aan HS en HSPG volledig verloren 
(Hoofdstuk 3). Het bleek dat de binding van anti-DNA 
antistoffen aan HS en HSPG niet een gevolg was van een directe 
binding (kruisreactie), maar veroorzaakt werd door een 
intermediaire ligand die zowel DNA als histonen bevat. Naar 
aanleiding van deze bevindingen moesten we ons aanvankelijke 
concept betreffende de kruisreactie van anti-DNA antistoffen 
met HS herzien en formuleerden we een nieuwe hypothese voor de 
binding van anti-DNA antistoffen in de glomerulus. Deze 
hypothese houdt in dat anti-DNA antistoffen immuuncomplexen 
kunnen vormen met DNA/histon partikels (nucleosomen), welke 
kunnen binden aan de GBM door de interactie van histonen met 
HS (Hoofdstuk 4). 
De binding van anti-DNA antistoffen aan HS lijkt klinische 
relevantie te hebben, aangezien we een associatie vonden 
tussen anti-heparan sulfaat reactiviteit in sera van SLE 
patiënten en het ontstaan van nefritis (Hoofdstuk 5). In het 
algemeen wordt aangenomen dat hoge spiegels van anti-DNA 
antistoffen gemeten met behulp van de Farr assay, die alleen 
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antistoffen met hoge aviditeit voor dubbelstrengs DNA 
detecteert, correleren met het ontwikkelen van 
nieraandoeningen. Wij hebben echter geen correlatie gevonden 
tussen reactiviteit in de anti-HS ELISA en anti-DNA spiegels 
gemeten in de Farr assay, alhoewel we nooit anti-HS reactivi-
teit hebben gevonden in Farr assay negatieve sera. Dit 
betekent dat alleen een subpopulatie van anti-DNA antistoffen 
kan binden aan HS. Gezien onze eerdere bevinding dat de 
binding van anti-DNA monoklonale antistoffen aan HS tot stand 
komt via nucleosomen, moesten we nagaan of de binding aan HS, 
gevonden in de sera, het resultaat was van histon/DNA/anti-DNA 
complexen gevormd tijdens de stolling van de bloedmonsters. 
Dit bleek niet het geval te zijn aangezien we dezelfde anti-HS 
reactiviteit vonden in gelijktijdig afgenomen serum- en 
plasmamonsters. Opzuivering onder dissociatieve condities 
verminderde zowel in de serum- als in de plasmamonsters de 
anti-HS reactiviteit aanzienlijk (>70%). Uit deze resultaten 
kan geconcludeerd worden dat nefritogene anti-DNA complexen, 
aanwezig in de circulatie van SLE patiënten voorafgaand aan 
het ontstaan van of een exacerbatie van SLE nefritis, 
gedetecteerd kunnen worden met behulp van de HS ELISA. 
Derhalve zou niet het voorkomen van hoog avide anti-DNA 
antistoffen in de circulatie op zichzelf, maar de aanwezigheid 
van histon/DNA/anti-DNA complexen, patiënten kunnen opsporen 
die het risico lopen op de ontwikkeling van nieraandoeningen. 
Onze nieuwe hypothese betreffende het mechanisme van immuun-
complexformatie van anti-DNA antistoffen in de glomerulus kon 
135 
worden bevestigd door renale perfusie studies in de rat, die 
aantonen dat de binding van anti-DNA antistoffen aan de GBM in 
vivo niet wordt veroorzaakt door directe binding van anti-DNA, 
maar tot stand komt via histonen en DNA (Hoofdstuk 6). 
Daarnaast hebben we een tweede mechanisme gevonden van 
glomerulaire binding van anti-DNA antistoffen, dat alleen werd 
waargenomen bij een monoklonale antistof met hoge aviditeit 
voor dubbelstrengs DNA. Deze binding was beperkt tot 
mesangiale gebieden en kwam tot stand via DNA alleen. Binding 
via beide mechanismen veroorzaakte een verhoogde albumine 
uitscheiding in de urine. Het is daarom aannemelijk dat beide 
mechanismen van anti-DNA depositie betrokken zijn bij de 
Pathogenese van SLE nefritis. 
Voor een nadere specificatie van de autoantistoffen die een 
rol spelen bij het ontstaan SLE nefritis, hebben we de 
nefritogene antistoffen gekarakteriseerd in twee muizemodellen 
van SLE nefritis (Hoofdstuk 7) . Antistoffen werden geëlueerd 
uit glomeruli afkomstig van aangetaste nieren. Vervolgens werd 
de reactiviteit met nucleaire antigenen (DNA en histonen) en 
met intrinsieke componenten van de GBM geanalyseerd. Naast 
anti-DNA antistoffen konden we antistoffen tegen histonen en 
tegen laminine, een andere belangrijke component van de GBM, 
aantonen in deze eluaten. Deze resultaten bevestigen dat 
nucleosomen waarschijnlijk betrokken zijn bij de depositie van 
antistoffen in de glomerulus. Naast deze twee verschillende 
anti-nucleaire antistoffen die indirect kunnen binden aan 
glomerulaire structuren, speelt mogelijk ook directe binding 
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van antistoffen aan laminine een rol in de Pathogenese van SLE 
nefritis. Of anti-histon en anti-laminine antistoffen naast 
anti-DNA ook betrokken zijn bij de ontwikkeling van SLE 
nefritis in de mens moet nog onderzocht worden. Deze 
bevindingen kunnen echter een belangrijke bijdrage leveren aan 
de opheldering van het mechanisme dat verantwoordelijk is voor 
het ontstaan van nieraandoeningen bij SLE patiënten. 
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